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A B S T R A C T
Background
Before extraction and synthetic chemistry were invented, musculoskeletal complaints were treated with preparations from medicinal
plants. They were either administered orally or topically. In contrast to the oral medicinal plant products, topicals act in part as
counterirritants or are toxic when given orally.
Objectives
To update the previous Cochrane review of herbal therapy for osteoarthritis from 2000 by evaluating the evidence on eAectiveness for
topical medicinal plant products.
Search methods
Databases for mainstream and complementary medicine were searched using terms to include all forms of arthritis combined with
medicinal plant products. We searched electronic databases (Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
AMED, CINAHL, ISI Web of Science, World Health Organization Clinical Trials Registry Platform) to February 2013, unrestricted by language.
We also searched the reference lists from retrieved trials.
Selection criteria
Randomised controlled trials of herbal interventions used topically, compared with inert (placebo) or active controls, in people with
osteoarthritis were included.
Data collection and analysis
Two review authors independently selected trials for inclusion, assessed the risk of bias of included studies and extracted data.
Main results
Seven studies (seven diAerent medicinal plant interventions; 785 participants) were included. Single studies (five studies, six interventions)
and non-comparable studies (two studies, one intervention) precluded pooling of results.
Moderate evidence from a single study of 174 people with hand osteoarthritis indicated that treatment with Arnica extract gel probably
results in similar benefits as treatment with ibuprofen (non-steroidal anti-inflammatory drug) with a similar number of adverse events.
Mean pain in the ibuprofen group was 44.2 points on a 100 point scale; treatment with Arnica gel reduced the pain by 4 points aNer three
weeks: mean diAerence (MD) -3.8 points (95% confidence intervals (CI) -10.1 to 2.5), absolute reduction 4% (10% reduction to 3% increase).
Hand function was 7.5 points on a 30 point scale in the ibuprofen-treated group; treatment with Arnica gel reduced function by 0.4 points
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(MD -0.4, 95% CI -1.75 to 0.95), absolute improvement 1% (6% improvement to 3% decline)). Total adverse events were higher in the Arnica
gel group (13% compared to 8% in the ibuprofen group): relative risk (RR) 1.65 (95% CI 0.72 to 3.76).
Moderate quality evidence from a single trial of 99 people with knee osteoarthritis indicated that compared with placebo, Capsicum extract
gel probably does not improve pain or knee function, and is commonly associated with treatment-related adverse events including skin
irritation and a burning sensation. At four weeks follow-up, mean pain in the placebo group was 46 points on a 100 point scale; treatment
with Capsicum extract reduced pain by 1 point (MD -1, 95% CI -6.8 to 4.8), absolute reduction of 1% (7% reduction to 5% increase). Mean
knee function in the placebo group was 34.8 points on a 96 point scale at four weeks; treatment with Capsicum extract improved function
by a mean of 2.6 points (MD -2.6, 95% CI -9.5 to 4.2), an absolute improvement of 3% (10% improvement to 4% decline). Adverse event
rates were greater in the Capsicum extract group (80% compared with 20% in the placebo group, rate ratio 4.12, 95% CI 3.30 to 5.17). The
number needed to treat to result in adverse events was 2 (95% CI 1 to 2).
Moderate evidence from a single trial of 220 people with knee osteoarthritis suggested that comfrey extract gel probably improves pain
without increasing adverse events. At three weeks, the mean pain in the placebo group was 83.5 points on a 100 point scale. Treatment
with comfrey reduced pain by a mean of 41.5 points (MD -41.5, 95% CI -48 to -34), an absolute reduction of 42% (34% to 48% reduction).
Function was not reported. Adverse events were similar: 6% (7/110) reported adverse events in the comfrey group compared with 14%
(15/110) in the placebo group (RR 0.47, 95% CI 0.20 to 1.10).
Although evidence from a single trial indicated that adhesive patches containing Chinese herbal mixtures FNZG and SJG may improve
pain and function, the clinical applicability of these findings are uncertain because participants were only treated and followed up for
seven days. We are also uncertain if other topical herbal products (Marhame-Mafasel compress, stinging nettle leaf) improve osteoarthritis
symptoms due to the very low quality evidence from single trials.
No serious side eAects were reported.
Authors' conclusions
Although the mechanism of action of the topical medicinal plant products provides a rationale basis for their use in the treatment of
osteoarthritis, the quality and quantity of current research studies of eAectiveness are insuAicient. Arnica gel probably improves symptoms
as eAectively as a gel containing non-steroidal anti-inflammatory drug, but with no better (and possibly worse) adverse event profile.
Comfrey extract gel probably improves pain, and Capsicum extract gel probably will not improve pain or function at the doses examined
in this review. Further high quality, fully powered studies are required to confirm the trends of eAectiveness identifed in studies so far.
P L A I N   L A N G U A G E   S U M M A R Y
Topical herbal therapy for treating osteoarthritis
This summary of a Cochrane review presents what we know from research about the eAects of herbal therapies applied to the skin in
people with osteoarthritis.
The review shows that in people with osteoarthritis:
Arnica gel probably improves pain and function as well as non-steroidal anti-inflammatory drugs do;
Capsicum extract gel probably will not improve pain or function more than placebo;
Comfrey extract gel probably improves pain more than placebo;
Chinese herbal patches probably improve pain and function slightly more than placebo.
Herbal therapies may cause side eAects; however we do not have precise information about side eAects and complications. This is
particularly true for rare but serious side eAects. Possible side eAects may include skin irritations.
What is osteoarthritis and what is herbal therapy?
Osteoarthritis (OA) is a disease of the joints (commonly knee, hip, hands). When joints lose cartilage, bone grows to try to repair the
damage. Instead of making things better, however, the bone grows abnormally and makes things worse. For example, the bone can become
misshapen and make the joint painful and limit movement. OA can aAect your physical function, particularly your ability to use your joints.
Herbal medicines are defined as finished, labeled medicinal products that contain as active ingredients aerial or underground parts of
plants, other plant material, or combinations thereof, whether in the crude state or as plant preparations (for example oils, tinctures).
Best estimate of what happens to patients with osteoarthritis who apply Arnica extract gel:
Arnica gel was compared to ibuprofen (a non-steroidal anti-inflammatory).
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Pain (higher scores mean more severe pain): people who applied Arnica rated their pain to be 3.8 points lower (10.1 points lower to 2.5
points higher) than people who applied ibuprofen. ANer 3 weeks of treatment, people who applied Arnica rated their pain to be 40.4 and
people who applied ibufrofen rated their pain to be 44.2 on a scale of 0 to 100.
Physical function (lower scores mean better function): people who applied Arnica rated their physical function to be 0.4 points lower (1.75
points lower to 0.95 points higher) than people who applied ibuprofen. ANer 3 weeks of treatment, people who applied Arnica rated their
physical function to be 7.1 on a scale of 0 to 30, and people who applied ibufrofen rated their physical function to be 7.5.
Side eAects: a greater proportion of people who applied Arnica reported side eAects than did those who applied ibuprofen. Fourteen out
of 105 people reported side eAects with Arnica, and 8 out of 99 people reported side eAects with ibuprofen.
Best estimate of what happens to patients with osteoarthritis who apply Capsicum extract gel
Capsicum extract gel was compared to placebo.
Pain (higher scores mean more severe pain): people who applied Capsicum rated their pain to be 1.0 point lower (6.76 points lower to 4.76
points higher) than people who applied placebo. ANer 4 weeks of treatment, people who applied Capsicum rated their pain to be 44.6, and
people who applied placebo rated their pain to be 45.6 on a scale of 0 to 100.
Physical function (lower scores mean better function): people who applied Capsicum rated their physical function to be 2.64 points lower
(9.51 points lower to 4.23 points higher) on a 0 to 96 point scale than people who applied placebo. ANer 4 weeks of treatment, people who
applied Capsicum rated their physical function to be 32.15 on a scale of 0 to 96, and people who applied ibufrofen rated their physical
function to be 34.79.
Side eAects: more adverse events were reported among people who applied Capsicum than for those who applied placebo. Of the 338
adverse events reported, 272 occurred in people who applied Capsicum and 66 occured in people who applied placebo.
Best estimate of what happens to patients with osteoarthritis who apply comfrey extract cream
Comfrey extract cream was compared to placebo.
Pain (higher scores mean more severe pain): people who applied comfrey rated their pain to be 16.3 points lower (20.08 to 12.58 points
lower) than people who applied placebo. ANer 3 weeks of treatment, people who applied comfrey rated their pain to be lower by 20.9
points from baseline, and people who applied placebo rated their pain to be lower by 4.6 points from baseline on a scale of 0 to 100.
Side eAects: a smaller proportion of people who applied comfrey reported side eAects than did those who applied placebo. Seven out of
110 people reported side eAects with comfrey, and 15 out of 110 people reported side eAects with placebo.
Chinese herbal medicine patches
Adhesive patches containing the Chinese herbal mixtures FNZG and SJG were compared to placebo. We are uncertain whether Chinese
herbal patches aAect osteoarthritis because this intervention was tested over seven days only.
Pain (higher scores mean worse or more severe pain): people who applied FNZG rated their pain to be 1.44 points lower (9.28 points lower
to 6.40 points higher) and people who applied SJG rated their pain to be 1.08 points lower (6.28 points lower to 8.40 points higher) than
people who applied placebo. People who applied FNZG rated their pain to be lower by 19.20 points from baseline, people who applied SJG
rated their pain to be lower by 16.04 points from baseline, and people who applied placebo rated their pain to be lower by 17.68 points
from baseline on a scale of 0 to 100.
Physical function (lower scores mean better function): people who applied FNZG rated their function to be 2.61 points lower (9.50 points
lower to 4.28 points higher) and people who applied SJG rated their function to be 2.97 points lower (9.60 points lower to 3.66 points
higher) than people who applied placebo. People who applied FNZG rated their physical function to be lower (better) by 5.04 points from
baseline, people who applied SJG rated their physical function to be lower (better) by 6.71 points from baseline, and people who applied
placebo rated their physical function to be lower (better) by 6.10 points from baseline on a scale of 0 to 96.
Side eAects: a greater proportion of people who applied herbal patches reported side eAects than did those who applied placebo patches.
Five out of 60 people reported side eAects with FNZG, 4 out of 60 people reported side eAects with SJG, and 0 out of 30 people reported
side eAects with placebo.
Other topical products
We are uncertain whether other topical herbal products aAect osteoarthritis pain and function because the evidence available from these
studies was of low to very low quality. FNZG patches were compared head-to-head with SJG patches. Marhame-Mafasel compress was
compared to placebo. Stinging nettle leaf was compared with two placebos in two diAerent studies of people with osteoarthritis of the
thumb or of the knee.
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Summary of findings for the main comparison.   Arnica versus ibuprofen for osteoarthritis of the hand
Arnica versus ibuprofen for osteoarthritis of the hand
Patient or population: patients with osteoarthritis of the hand
Settings: Community, Switzerland
Intervention: Arnica montana
Comparison: Ibuprofen1
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Ibuprofen Arnica
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
NNT (95% CI)
Pain
VAS 0 to 100 (higher scores means
worse)
Follow-up: mean 3 weeks.
The mean pain in the
control group was
44.2 points on a 100
point scale.
The mean pain in the in-
tervention group was
3.8 lower
(10.1 lower to 2.5 high-
er).
  174
(1 study)
⊕⊕⊕⊝
moderate1, 2,
3
Absolute reduction in
pain was 4% (10% re-
duction to 3% increase);
relative reduction in
pain 5% (15% reduction
to 4% increase); NNT n/
a.4
Function
Hand algofunctional index (higher
scores means worse)
Follow-up: mean 3 weeks.
The mean function
in the control group
was 7.5 points on a
30 point scale.
The mean hand func-
tion in the intervention
group was
0.4 lower
(1.75 lower to 0.95 high-
er).
  174
(1 study)
⊕⊕⊕⊝
moderate1, 2,
3
Absolute functional im-
provement was 1% (6%
improvement to 3% de-
cline); relative functional
improvement was negli-
gible5; NNT n/a.4
Study populationAdverse events
Participants (n) reported events
Follow-up: mean 3 weeks 81 per 1000 133 per 1000
(58 to 278)
RR 1.65 (0.72
to 3.76)
204
(1 study)
⊕⊕⊕⊝
moderate1, 2,
3
Absolute risk of adverse
events was 5% higher
in the Arnica group (3%
lower to 14% higher);
NNT n/a. 4
Adverse events
Participants (n) withdrew due to ad-
verse effects
    Not estimable     Reported NIL with-
drawals due to adverse
events.6
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Adverse events
Participants (n) reported serious ad-
verse events
    Not estimable     Reported NIL serious ad-
verse events.5
Quality of life Quality of Life not measured.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Single study. Treatment eAect crosses midline (no eAect).
2 Non-inferiority hypothesis: that Arnica is not inferior to ibuprofen for the treatment of osteoarthritis of the hand.
3 Confirmatory design, statistical power 80%, alpha 0.024.
4 Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial
oAice). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).
5 Negligible percentage change less than 1%.
6 Reported one case of back pain due to a fall, leading to withdrawal from the study; this event is neither withdrawal due to adverse event, nor a serious adverse event, as defined
for this review.
 
 
Summary of findings 2.   Capsicum for osteoarthritis of the knee
Capsicum for osteoarthritis of the knee
Patient or population: patients with osteoarthritis of the knee
Settings: Community, Thailand
Intervention: Capsicum extract
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Capsicum extract
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
NNT (95% CI)
Pain
VAS 0-100 (higher means worse)
Follow-up: mean 4 weeks
The mean pain in
the control group
The mean pain in the
intervention group
was
  99
(1 study)
⊕⊕⊕⊝
moderate1, 2
Absolute reduction in pain
was 1% (7% reduction to 5%
increase); relative reduction
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was 45.6 points on
a 100 point scale.
1 lower
(6.76 lower to 4.76
higher)
in pain 2% (10% reduction to
7% increase); NNT n/a.5
Function
WOMAC 0-4 (Function; higher means
worse)
Follow-up: mean 4 weeks2
Measured, but not
reported.
Measured, but not re-
ported.
Not estimable 99
(1 study)
⊕⊕⊕⊝
moderate1, 2
Crossover trial: WOMAC 0-4
(Function) reported for whole
trial only (ie: both arms of
crossover combined).
Function
WOMAC 0-4 (Overall; higher means
worse)
Follow-up: mean 4 weeks2
The mean func-
tion in the control
group was 34.79 on
a 96 point scale.
The mean function in
the intervention group
was
2.64 lower
(9.51 lower to 4.23
higher)
  99
(1 study)
⊕⊕⊕⊝
moderate1, 2
Absolute functional improve-
ment 3% (10% improvement
to 4% decline); relative func-
tional improvement 5% (19%
improvement to 9% decline);
NNT n/a. 5
Study populationAdverse events
Event episodes (n) reported
Follow-up: mean 4 weeks2 195 per 1000 805 per 1000
(738 to 858)
Rate Ratio
4.12 (3.30 to
5.17)
676
(1 study)
⊕⊕⊕⊝
moderate1, 2,
3
Absolute risk of adverse
events was 61% higher in the
capsaicin group (55% to 67%
higher); NNT = 1.64 (95% CI
1.82 to 1.50).
Adverse events
Participants (n) withdrew due to ad-
verse effects
    Not estimable     Reported NIL withdrawals
due to adverse events.
Adverse events
Participants (n) reported serious ad-
verse events
    Not estimable     Reported NIL serious adverse
events.
Quality of Life Not measured or reported.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 Single study. Treatment eAect crosses midline (no eAect).
2 Randomisation and allocation concealment inadequately reported. Per protocol analysis only.
3 Crossover trial: 4 week intervention arms plus 1 week washout.
4 Capsicum extract gel stimulates heat receptors in the skin, which is part of the eAect of this topical agent. Including "burning sensations" among the reported adverse events
may have inflated this outcome. InsuAicient blinding to the intervention may have confounded the reporting of adverse events.
5 Number needed to treat (NNT) = not applicable (n/a) when result is not statistically significant. NNT for continuous outcomes calculated using Wells Calculator (CMSG editorial
oAice). NNT for dichotomous outcomes calculated using Cates NNT calculator (http://www.nntonline.net/visualrx/).
 
 
Summary of findings 3.   Comfrey for osteoarthritis of the knee
Comfrey for osteoarthritis of the knee
Patient or population: patients with osteoarthritis of the knee
Settings: Community, Germany
Intervention: Comfrey
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Comfrey
Relative ef-
fect
(95% CI)
No of Partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Pain
VAS 0-100 (higher means
worse)
Follow-up: mean 3 weeks
The mean pain
in the control
group was 83.5
points on 100
point scale.1
The mean pain:
change from base-
line in the interven-
tion groups was
41.5lower
(34 to 48 lower)
  220
(1 study)
⊕⊕⊕⊝
moder-
ate1,2,3
Absolute reduction in pain was 42% (34%
to 48% reduction); relative reduction in
pain 48% (36% to 51% reduction); NNT =
1.84 (95% CI 1.7 to 2.1).4
Function: change from
baseline
WOMAC VAS (Function;
higher means worse)
Follow-up: mean 3 weeks
Not estimable 2 Not estimable 2 Not estimable
2
220
(1 study)
⊕⊕⊕⊝
moderate1,2
Not estimable 2
Study populationAdverse events
Participants (n) reported
adverse events
Follow-up: mean 3 weeks
136 per 1000 64 per 1000
(26 to 148)
RR 0.47 (0.20
to 1.10)
220
(1 study)
⊕⊕⊕⊝
moderate 2, 3
Absolute risk of adverse events was 7%
lower in the comfrey group (15% lower to
1% higher); NNT n/a. 4
Adverse events
Participants (n) withdrew
due to adverse effects
    Not estimable     Withdrawal due to adverse events not re-
ported.
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Adverse events
Participants (n) reported se-
rious adverse events
    Not estimable     Reported NIL serious adverse events.
Quality of life
SF-36 4
Not estimable 2 Not estimable 2 Not estimable
2
220
(1 study)
⊕⊕⊕⊝
moderate2
Not estimable 2
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Standard deviations for pain measures were estimated from graphical data.
2 Most outcome data reported as change scores, percentages, and graphs only, insuAicient for extraction.
3 Criteria for diagnosis of OA not specified at baseline. Diagnosis not consistent with ACR criteria, but likely to be OA.
4 SF-36 has a recall period of 4 weeks. Participants are asked to recall their health perceptions "...over the last 4 weeks". Use of this outcome measure to investigate interventions
less than 4 weeks duration is likely to be imprecise.
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B A C K G R O U N D
At times where extraction and synthetic chemistry were not yet
invented, musculoskeletal complaints were treated all over the
world with preparations from medicinal plants. Due to a legal
decision in Germany in 1978, the Commission E of the Federal
Health Agency re-evaluated the herbal drugs (Blumenthal 1998).
Table 1 summarizes the monographs of approved medicinal plant
parts and their preparations for topical use in the treatment of
osteoarthritis (OA) complaints. In the course of the harmonization
within Europe, the monographs of the European Scientific
Cooperative on Phytotherapy (ESCOP) appeared continuously
thereaNer and were summarized in the second edition and a
supplement (ESCOP 2003; ESCOP 2009) (Table 2). Parallel to
this, the American Herbal Pharmacopeia (www.herbal-ahp.org)
has been publishing comprehensive monographs accompanied
by a Therapeutic Compendium since 1996, and the WHO
its monographs on selected medicinal plants since 1999
(http://apps.who.int/medicinedocs/en/d/Js2200e/). Although the
ESCOP, American and WHO monographs are not oAicial, they
provide scientific information on the safety, eAicacy and
quality of medicinal plants and provide recommendations for
their use in clinical practice (for example doses, types of
preparation, warnings). In contrast, the European Medicines
Agency monographs (EMA monographs) serve as a guidance for
application dossiers to obtain marketing authorization by the
regulatory authorities of the individual countries in the European
Union. 
In the previous Cochrane review on herbal medicines for OA (Little
2000), oral and topical herbal medicines were considered together.
However, due to the fact that the mechanism of action of topical
medicinal plant products is diAerent from that of oral products, in
that they act as counterirritants via the skin or because they are
toxic when orally applied, a separation of topical and oral medicinal
plant preparations seemed advisable. For example, nettle leaf is
covered with needle-like hairs that on contact pierce the skin
injecting irritant substances like formic acid, acetic acid, serotonin
or 5-hydroxytryptamine, histamine and acetylcholine (Anonymous
1998), which cause an irritant skin reaction. Already in the middle
ages urtication (beating with nettle) belonged to the armentarium
of treatments for (osteo)arthritic pain.
Menthol, contained in peppermint or other mint oils, is a
topical counterirritant (Yosipovitch 1996). The terpene increases
the perception of cooling and attenuates the perception of
moderate warming (Green 1992) by triggering the cold-sensitive
Transient Receptor Potential Melastatine 8 (TRPM8) receptors in
skin sensory neurons (Yudin 2012). TRP-Ankyrin1 (A1), another
cold-sensing channel, is also involved in the menthol cooling
sensation (Karashima 2007). The activation of TRPM8 mediates
the menthol spasmolytic eAect (Johnson 2009). In vitro studies
demonstrated menthol inhibition of the arachidonic acid cascade
(cyclooxygenase-2 (COX-2), lipooxygenase) and cytokine release
(Juergens 1998). Local anaesthetic (Galeotti 2001), antioxidative
(Ka 2005) and analgesic (Taniguchi 1994) actions are other targets of
the menthol mechanism of action, the latter based on a weak kappa
opioid receptor agonistic eAect (Galeotti 2002) and cumulative
inactivation of voltage-gated sodium channels (Gaudioso 2012).
The capsaicinoids, the active principle of Capsicum species, act
via the heat-sensitive Transient Receptor Potential Vanilloid-1
(TRPV1) receptors (Hayes 2000). Binding of capsaicin to this
target is accompanied by a decrease in membrane resistance,
depolarization and activation of synaptosomal neurotransmitter
release (Buck & Burks 1986; Huang 2008; Sauer 2001; Zhao 1992).
Following the initial activation, which is oNen associated with
heat sensation, desensitation and depletion of neurotransmitters
produce the capsaicinoid (expressed as capsaicin) analgesic eAect.
If capsaicin exposure persists, nerve terminals will degenerate
(defunctionalization) (Dedov 2000; Dedov 2001; Nolano 1999),
which causes the prolonged analgesic eAect aNer the end of
treatment. Other capsaicin eAects include the inhibition of
inducible COX-2 mRNA expression (Kim 2003) and LOX (Flynn 1986)
and a free radical scavenging activity (Galano 2012; Luqman 2006).
Arnica and comfrey do not act as counterirritants. However, both
are for topical use due to systemic toxicity (ESCOP 2003; ESCOP
2009) and should only be applied to intact skin. Arnica and comfrey
inhibit COX-1 and COX-2 and have an antioxidative potential
(ESCOP 2009; Schröder 1990; Verma 2010). So far, inhibition of LOX
(Tornhamre 2001), elastase (Siedle 2002; Siedle 2003), cytokines
(Jäger 2009; Klaas 2002; Lyss 1997), transcription factor NF-kappaB
(Ekenäs 2008) and AP1 (Jäger 2009) has, however, only been
demonstrated for the Arnica species. Some eAects seem to be likely
for comfrey, for example elastase inhibition (Melzig 2005), based
on the comfrey ingredient rosmarinic acid for which inhibition
of cytokines (Lee 2006) and anti-inflammatory activity has been
demonstrated in various animal experiments (Englberger 1988;
Moon 2010).
Description of the condition
Osteoarthritis (OA) is characterized by degeneration of the joints,
for example the hip, knee and hand. The condition is widespread.
Lawrence and co-workers (Lawrence 2008) estimated that among
US adults, nearly 27 million had clinical osteoarthritis in 2005
(up from the estimate of 21 million for 1995). Women are more
oNen aAected with OA than men, and prevalence increases
with increasing age. Overweight and heavy physical work may
explain OA in some cases, but non-mechanical factors and genetic
disposition are involved as well (van den Berg 2011; Zhang 2010).
Diagnostically, primary OA is distinguished from secondary OA
induced by traumatic events and endocrine or metabolic disorders.
Both primary and secondary forms result in impaired quality
of life due to pain and physical disability (Schmitz 2010). The
OMERACT-Osteroarthritis Research Society International (OARSI)
response criteria combine pain and functional impairments in the
identification of treatment response (Pham 2003; Pham 2004) but
unfortunately response criteria are not universally considered in
clinical studies, making eAicacy comparisons diAicult.
Description of the intervention
For the purpose of this review we have adopted the World Health
Organization (WHO) guidelines for the defintion of medicinal plant
products, that is, "...finished, labeled, medicinal products that
contain as active ingredients, aerial or underground parts of plants,
or other plant material, or combinations thereof, whether in the
crude state or as plant preparations. Plant preparations include
comminuted or powdered plant materials, extracts, tinctures,
fatty or essential oils, and any other substances of this nature.
Herbal medicines may contain excipients in addition to the
active ingredients. Medicines containing plant material combined
with chemically defined active substances, including chemically
Topical herbal therapies for treating osteoarthritis (Review)
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defined, isolated constituents of plants, are not considered to be
herbal medicines." The WHO also notes that "exceptionally, in
some countries herbal medicines may also contain, by tradition,
natural organic or inorganic active ingredients which are not of
plant origin", however in this review we have applied the strict
definition and excluded herbal products combined with non-herbal
materials. (apps.who.int/medicinedocs/en/d/Jh2984e).
How the intervention might work
Medicinal plant products used topically for the treatment of OA act
as skin irritants (for example Capsicum extract, stinging nettle leaf)
and may also act via the same pathways known for oral medicinal
plant products, including inhibition of cyclooxygenase-1 and 2
(COX-1, COX-2), lipoxygenase (LOX), pro-inflammatory cytokines
and enzymes that participate in cartilage destruction, such as
elastase and hyaluronidase (for example Capsicum, Arnica, comfrey
extracts) (Cameron 2009). Some broad mechanisms of action have
been demonstrated in experimental studies (see Background) but
the mechanisms have not yet been elucidated in full detail.
Why it is important to do this review
Topical medicinal plant preparations are part of the armentarium
of traditional treatments used by patients suAering from rheumatic
pain conditions. The eAectiveness of some medicinal plant
products is unknown or unclear, and may be associated with risks
of harm. This review is important to summarize the evidence
of eAectiveness of medicinal plant products used topically for
OA, and to update the information on these products that is
currently captured in the monographs (see Table 1; Table 2). We
have undertaken this research to investigate the eAectiveness and
adverse side eAects of these products in the hope that patients
with OA and their healthcare providers may make more informed
decisions about the usefulness of these interventions.
In the previous Cochrane review on herbal medicines for OA
(Little 2000), oral and topical herbal medicines were considered
together. When the update of this review became particularly large,
a separation of topical and oral medicinal plant products seemed
advisable because a) only oral products are purported to have
any eAect on joint structure, b) topical herbal medicines may act
as counterirritants via the skin (for example nettle, peppermint,
Capsicum), and c) some products cannot be administered orally
due to systemic toxicity (Arnica, comfrey).
O B J E C T I V E S
To update the existing Cochrane systematic review (Little 2000) by
evaluating the evidence of eAectiveness for topical medicinal plant
products for the treament of osteoarthritis (OA) by adding data from
relevant randomised controlled trials published in the period from
January 2000 to February 2013.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised, controlled (placebo or active control), parallel
and crossover trials examining the eAects of topical herbal
interventions for treating OA.
Types of participants
All persons diagnosed with OA according to the American College
of Rheumatology (ACR) criteria (Altman 1986; Altman 1990; Altman
1991) or the equivalent European League Against Rheumatism
(EULAR) criteria (Zhang 2009; Zhang 2010a). Studies with samples
defined according to vague descriptions (for example 'joint pain')
were not considered. Studies with participant samples defined
according to incomplete or partial ACR or EULAR criteria were
included, and notes were provided to identify possible weaknesses
in sample selection in these studies.
Types of interventions
Any topically applied herbal intervention compared with an inert
(placebo) or active control was included. Herbal intervention
included any plant preparation (whole, powder, extract,
standardised mixture) but excluded homeopathy, aromatherapy,
or any preparation of synthetic origin.
In the methods published for the original review (Little 2000) herbal
therapies used in conjunction with other treatments or combined
with a non-herbal substance were also to be included if the eAect
of the non-herbal intervention was consistent among all groups
and quantifiable such that the eAect of the herbal intervention
could be determined. In this review, however, we have confined
interventions to those that comply with the WHO definition of
herbal (http://apps.who.int/medicinedocs/en/d/Jh2984e/1.html).
According to WHO, herbal therapy combined with a non-herbal
substance is no longer herbal treatment. This definition is
important because non-herbal substances may interact with the
active principle (sum of action of all ingredients) and change
eAects, potency and safety profile. Even if the non-herbal substance
occurs in the same concentration in the placebo control, as is
the case in two excluded studies (Gemmell 2003, McKay 2003),
the intervention-control comparison is not valid because the
non-herbal substance may enhance the absorption of individual
ingredients of the active principle or potentiate or reverse the eAect
of individual ingredients, thus changing the action of the active
principle and not the placebo.
Types of outcome measures
The main outcome measures considered were consistent with
those used across Cochrane Musculoskeletal Group (CMSG)
systematic reviews of interventions for OA: pain, function, adverse
events, and quality of life (Altman 1996; Pham 2004).
To assess the benefits of treatment:
• pain, measured on a visual analogue scale (VAS) (0 to 100),
WOMAC pain subscale (0 to 4 or VAS 0 to 100), numerical rating
scale (0 to 3), or other pain scales;• physical function, measured by a VAS (0 to 100), WOMAC function
subscale (0 to 4 or VAS 0 to 100), algofunctional index (0 to 3), or
other validated functional scales.
To assess the safety of treatment:
• number of participants reporting any adverse event.
Minor outcomes included:
• general well-being or satisfaction indicator;• withdrawals due to adverse events;
Topical herbal therapies for treating osteoarthritis (Review)
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• serious adverse events;• quality of life measured by the Short Form (SF)-36 or other
validated scales.
We included the following outcomes in the summary of findings
tables (derived from the list of outcomes recommended by the
CMSG for inclusion in reviews of interventions for osteoarthritis):
pain, function, number of participants experiencing any adverse
event, withdrawals due to adverse events, serious adverse events,
and quality of life. Because there is no purported mechanism
for topical herbal medicines to alter joint structure in OA, we
omitted radiographic joint changes as a reported outcome from the
summary of findings tables.
Search methods for identification of studies
Electronic searches
For this review update we searched the following electronic
databases from the date of the last search in the previously
published version of the review to November 2008, and updated the
search again on 21 May 2009, 14 December 2010, 16 May 2011, 30
November 2011, 15 June 2012, and finally on 25 and 27 February
2013.
1. Cochrane Central Register of Controlled Trials (CENTRAL) (part
of The Cochrane Library, accessed 25 February 2013).
2. DARE (part of The Cochrane Library, accessed 25 February 2013).
3. MEDLINE (via Ovid, 2000 to 25 February 2013).
4. MEDLINE   (Ovid MEDLINE® In-Process & Other Non-Indexed
Citations, to 25 February 2013).
5. EMBASE (via Ovid 2000 to 2011 Week 47)
6. CINAHL (via Ovid 2000 to 2008 Week 5; via EBSCO Host 2008 to
27 February 2013).
7. AMED (via Ovid, 1985 to 30 November 2011).
8. ISI Web of Knowledge (2000 to 27 February 2013).
9. Dissertation Abstracts, ProQuest (2000 to 27 February 2013).
10.WHO International Clinical Trials Registry Platform,
(apps.who.int/trialsearch accessed 27 February 2013).
Thesaurus and free text searches appropriate to each database
were performed to combine terms describing OA and terms
describing herbal medicine. No methodological filter was applied
and the search was not limited by language.
The full search strategies for each database are outlined in
Appendix 1.
Searching other resources
We searched reference lists of included trials for any other potential
studies.
Data collection and analysis
Selection of studies
This review was an update of a previous review. Two authors of
the original review (CL, TP) and two other colleagues (JG, AB)
made some contributions to this review and are acknowledged
here as investigators, but because these investigators did not
contribute to the totality of the review they are identified in the
Acknowledgements rather than listed as authors of this review.
All titles and abstracts identified from electronic databases
and other searches were independently examined by three
investigators (MC, SC, CL). The full manuscript was retrieved for
each record that had the possibility of meeting the review criteria.
Three investigators (MC, SC, CL) independently assessed the
eligibility of retrieved studies for the review according to the
inclusion criteria.
Data extraction and management
Data were extracted from each eligible study by two review authors
acting independently. Because of the length of time taken to
complete this review, and the associated review of oral medicinal
plant products for OA, three investigators (MC, SC, TP) contributed
to the data extraction.
Two review authors (MC, SC) independently extracted the following
data from the included trials and entered the data into RevMan 5:
1) trial characteristics including size and location of the trial, and
source of funding;
2) characteristics of the study population including age, and
characteristics of the disease including diagnosis criteria and
disease duration;
3) characteristics of the therapy in all trial arms including type and
dose of therapy;
4) risk of bias domains as outlined in 'Assessment of risk of bias in
included studies', below;
5) outcome measures as mean and standard deviation for
continuous outcomes, and number of events for dichotomous
outcomes (as outlined in Types of outcome measures).
If data were provided for a trial on more than one pain scale,
we referred to a previously described hierarchy of pain-related
outcomes (Juni 2006; Reichenbach 2007) and extracted data on the
pain scale that was highest on this list:
1. global pain;
2. pain on walking;
3. Western Ontario and McMaster Universities Index of
Osteoarthritis (WOMAC) osteoarthritis index pain subscore;
4. composite pain scores other than WOMAC;
5. pain on activities other than walking;
6. rest pain or pain during the night;
7. WOMAC global algofunctional score;
8. Lequesne osteoarthritis index global score;
9. other algofunctional scale;
10.patient's global assessment;
11.physician's global assessment.
If data on more than one function scale were provided for a trial, we
extracted data according to the hierarchy presented below:
1. global disability score;
2. walking disability;
3. WOMAC disability subscore;
4. composite disability scores other than WOMAC;
Topical herbal therapies for treating osteoarthritis (Review)
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5. disability other than walking;
6. WOMAC global scale;
7. Lequesne osteoarthritis index global score;
8. other algofunctional scale;
9. patient’s global assessment;
10.physician’s global assessment.
If pain or function outcomes were reported at several time points,
we extracted the measure at the end of the intervention as the main
outcome.
If data on more than one quality of life scale were provided for a
trial, we extracted data according to the hierarchy presented below:
1. SF-36;
2. EuroQoL;
3. SIP (Sickness Impact Profile);
4. NHP (Nottingham Health Profile).
Adverse events were measured as the number of patients
experiencing any adverse event, patients who were withdrawn or
dropped out because of adverse events, and patients experiencing
any serious adverse events. Serious adverse events were defined
as events resulting in in-patient hospitalisation, prolongation
of hospitalisation, persistent or significant disability, congenital
abnormality or birth defect of oAspring, life-threatening events, or
death.
If additional data were required, we contacted the trial authors
to obtain these data. Some data were converted to normalised
scales prior to extraction and reporting. Where data were imputed
or calculated (for example standard deviations calculated from
standard errors, P values, or confidence intervals; or imputed from
graphs or from standard deviations in other trials) we reported
these adjustments (see Characteristics of included studies). Any
disagreements were resolved by consensus.
Assessment of risk of bias in included studies
Two review investigators (MC, SC) independently assessed
the risk of bias of each included trial against key criteria:
random sequence generation; allocation concealment; blinding
of participants, personnel and outcome assessors; incomplete
outcome data; selective outcome reporting; and other sources of
bias, in accordance with methods recommended by The Cochrane
Collaboration (Higgins 2011). Each of these criteria were explicitly
judged as: (a) low, (b) unclear (either lack of information or
uncertainty over the potential for bias), or (c) high risk of bias.
Potential disagreements were discussed and resolved by referring
to the original protocol and, if necessary, arbitration by member(s)
of the editorial group.
Measures of treatment e>ect
When possible, the analyses were based on intention-to-treat data
(outcomes provided for every randomised participant) from the
individual trials. For each trial, we presented outcome data as
point estimates with means and standard deviations for continuous
outcomes and risk ratios (RRs) with corresponding 95% confidence
intervals (CIs) for dichotomous outcomes. Where possible, for
continuous outcomes we extracted end of treatment scores rather
than change from baseline scores. For continuous data, results
were presented as mean diAerences (MDs) and 95% CIs. We had
planned that when diAerent scales were used to measure the same
outcome or concept, standardised mean diAerence (SMD) would be
used.
Unit of analysis issues
Where a study was defined as a crossover trial, data were extracted
only up to the point of crossover given the potential for carry-over
eAects of these particluar interventions to bias the treatment eAect
following crossover.
Dealing with missing data
For dichotomous outcomes, we used the number randomised as
the denominator and made the assumption that any participants
missing at the end of treatment did not have a positive outcome.
For continuous outcomes with no standard deviation reported, if
possible we calculated standard deviations from standard errors,
P values, or CIs. For one study we converted the VAS data from a
10 cm scale to a 100 mm scale (Kosuwon 2010), and for another
study we estimated means and standard deviations from graphical
data (Grube 2007). Details of data conversion and imputation
are explained in the characteristics of included studies and the
associated table (see table Characteristics of included studies).
Assessment of heterogeneity
We assessed included trials for clinical homogeneity in terms of
participants, interventions and comparators. For studies judged
as clinically homogeneous, we quantified the possible magnitude
of inconsistency (that is heterogeneity) across studies using the
I2 statistic, with a rough guide for interpretation as follows: 0%
to 40% might not be important; 30% to 60% may represent
moderate heterogeneity; 50% to 90% may represent substantial
heterogeneity; 75% to 100% considerable heterogeneity (Deeks
2011).
Assessment of reporting biases
To examine the possibility of publication bias, we planned to
construct funnel plots if at least 10 studies were available for the
meta analysis of a primary outcome, however we identified too few
trials for this analysis.
We planned to assess the presence of small study bias in the overall
meta-analysis by checking if the random-eAects model estimate
of the intervention eAect was more beneficial than the fixed-eAect
model estimate, but again there were too few trials for this analysis.
Data synthesis
As far as data extraction was possible, descriptive results are
reported for all included studies. No studies could be subject to
meta-analysis.
Subgroup analysis and investigation of heterogeneity
Our original plan, in order to explain the heterogeneity between
the results of the included studies, was to included subgroup
analyses by type and length of intervention. Once the review was
divided into two reviews, covering topical and oral interventions
separately, there were insuAicient data in the trials of topical
interventions to justify subgroup analyses according to time of
intervention.
Topical herbal therapies for treating osteoarthritis (Review)
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Sensitivity analysis
We planned a sensitivity analysis to investigate the robustness of
the treatment eAect on pain and function relative to allocation
concealment and participant blinding by removing the trials that
reported inadequate or unclear allocation concealment and lack of
participant blinding from the meta-analysis to see if this changed
the overall treatment eAect. There were insuAicent data to perform
these analyses.
Summary of findings
See: Summary of findings for the main comparison; Summary of
findings 2; Summary of findings 3.
The main results (pain, function, adverse events, withdrawals due
to adverse events, serious adverse events, quality of life) of the
review are presented in summary of findings tables (Schunemann
2011a). The overall grading of the evidence using the GRADE
approach to classify the evidence for each herbal intervention,
as: (a) high, (b) moderate, (c) low, or (d) very low, is included as
an indication of confidence in the results of the studies. EAect
sizes were reported as relative risk and as number needed to treat
(Schunemann 2011b).
R E S U L T S
Description of studies
See: Characteristics of included studies.
See: Characteristics of excluded studies.
A total of seven new studies were identified for inclusion in this
updated review (Grube 2007; Kosuwon 2010; Randall 2000; Randall
2008; Soltanian 2010; Wang 2012; Widrig 2007). The one study of
topical capsaicin that was included in the original review (Deal
1991) was excluded from this review when additional information
that was provided by the manufacturer allowed us to identify that
the capsaicin was extracted (that is a single extracted ingredient,
which is not herbal) and not an extract from Capsicum fruits. The
term capsaicin may be used to refer to capsaicinoids (extract,
expressed as capsaicin) or synthetic or extracted capsaicin (single
ingredient).
Two studies were of parallel design, with two groups comparing
a herbal intervention to a placebo (inert) control (Grube 2007;
Randall 2008). One study compared a herbal product with an
active control (Widrig 2007). Another study compared two herbal
products against each other as well as against a placebo control in a
three-arm trial (Wang 2012). Three studies used crossover designs
(Kosuwon 2010; Randall 2000; Soltanian 2010). Four studies were
of a confirmatory design, with suAicient statistical power (80%)
to identify significant eAects at the alpha level 0.05 (Grube 2007;
Kosuwon 2010; Wang 2012; Widrig 2007). The other three studies
were exploratory, showing trends of eAectiveness only.
The inclusion of three studies is open to question because: (a)
participants entered the study with a presumptive diagnosis,
not confirmed at baseline, or (b) the criteria by which OA was
established were incomplete or inconsistent with ACR or EULAR
requirements (Grube 2007; Randall 2000; Randall 2008).
Results of the search
This review was formed from the division of a broader review of
herbal therapies for the treatment of OA. In the original review
both topical and oral medicinal plant products were considered.
The search strategy for this updated review was structured from
the protocol used in the original review. The searches for this
review update have been repeated several times since 2005. The
most recent full search (December 2011) was completed before
the current review was divided into two parts. Therefore, it is not
possible to give an entirely accurate presentation of the search
results as the number of references identified from the search.
In the most recent full search of all databases we identified,
aNer the removal of duplicates, 288 abstracts on topical or oral
herbal medicines in the treatment of OA. From these abstracts, we
identified only one new study that fulfilled the inclusion criteria
for this divided review of topical medicinal plant products only. In
more recent repeat searches (June 2012 and February 2013) we
identified 1771 abstracts, reduced to 159 abstracts aNer removal
of duplicates from previous searches, and from these abstracts
four new studies were identified: one that fulfilled the criteria for
inclusion, one that was excluded, and two studies available only in
abstract form that are currently awaiting classification. See Figure
1 for our best estimate of results from the searches.
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Figure 1.   Study flow diagram.
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Included studies
See: Characteristics of included studies.
Medicinal plant products used for the treatment of OA included
crude stinging nettle leaf, standardised extracts from single
plants (Arnica, Capsicum, and comfrey), and three mixtures of
preparations from multiple plants known as Marhame-Mafasel,
Fufang Nanxing Zhitong Gao (FNZG), and Shangshi Jietong Gao
(SJG) (proprietary names) (see Table 3 for preparation details of all
products).
A few key outcome measures were used but the reporting of
measures diAered among studies limiting the utility of studies
for meta-analysis. All VAS were 100 mm lines, with anchor points
identified as 0 (nil symptom) and 100 (worst possible symtom),
but some authors reported VAS scores on a centimetre scale in the
range 0 to 10. For ease of comparison between trials, we converted
all VAS data to the 0 to 100 mm scale.
Several studies used WOMAC, but this index may be used with
two possible scoring methods: a battery of 0 to 4 Likert scales
or a battery of 100 mm VAS. Typically, the Likert scale scores
are presented as aggregate scores (sums) for each of the three
subscales (pain subscore range 0 to 20, stiAness subscore range
0 to 8, physical function subscore range 0 to 68), whereas the
VAS are converted to normalised units (means) for each subscale
(all subscales scored 0 to 100). Although both scoring systems
are acceptable for clinical and research use, there is no agreed
conversion ratio between them so studies using diAering systems
are not comparable. Specific details of all data conversions are
included in the Characteristics of included studies.
Excluded studies
See: Characteristics of excluded studies.
Reasons for excluding studies were: (a) not a randomised controlled
trial (Rayburn 2009; Sagar 1988; Saley 1987; Yuelong 2011), (b)
review or discussion paper (Kielczynski 1997; Linsheng 1997; Long
2001), or (c) not a herbal intervention (Altman 1994; Gemmell 2003;
McCarthy 1992; McCleane 2000; McKay 2003; Schnitzer 1994; Smith
2011).
Risk of bias in included studies
See: Characteristics of included studies, 'Risk of bias' tables.
The methodological quality of each study was assessed
independently by two review authors according to the criteria
described in the methods (Higgins 2011; Schunemann 2011a). The
quality of the included studies was variable and should be taken
into account when interpreting the results. See Figure 2 for a
summary of the risk of bias assessment.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Only one study adequately met all six validity criteria (Widrig
2007) and was classified as having low risk of bias. All studies
were described as randomised. The method of randomisation
was not reported in five studies (Grube 2007; Kosuwon 2010;
Randall 2000; Wang 2012; Widrig 2007) but two of these studies
were conducted in Germany and reported compliance with the
International Harmonisation Conference Good Clinical Practice
(IHC GCP) guidelines, which is anchored in German law and requires
that adequate randomisation, allocation concealment and blinding
were undertaken. Risk of bias in these two studies was assessed as
low for these criteria (Grube 2007; Widrig 2007).
Allocation
Selection bias was rated as low in studies that recruited patients
with diagnoses of OA confirmed according to ACR or EULAR criteria
(Altman 1986; Altman 1990; Altman 1991; Zhang 2009; Zhang
2010a). In some studies, diagnostic criteria applied at recruitment
were not labelled as ACR or EULAR criteria but were described in
suAicient detail to be confident that they were fully consistent with
the recommendations of these authorities or they were endorsed
by other authorities (for example Chinese Orthopaedic Association
criteria) (Wang 2012).
In two studies, ACR or EULAR criteria were not fully considered and
these studies have been downgraded to unclear risk of selection
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bias (Grube 2007; Randall 2008). In one study, selection criteria
were so broad as to almost certainly have included recruitment
of participants with conditions other than OA (Randall 2000). This
study has been classified as having high risk of bias.
Allocation concealment was poorly described in most studies.
Allocation concealment was assessed according to the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We attributed low risk of bias to one study (Randall 2008) in which
allocation concealment was inferred from the description of the
methods and the two studies in which it could reasonably be
expected through reported compliance with ICH GCP guidelines
(see Other potential sources of bias) (Grube 2007; Widrig 2007).
Allocation concealment could not be determined in any other
study; neither could failure to conceal allocation be determined.
These studies have been classified as having unclear risk of bias for
this criterion.
Blinding
Low risk of bias has been attributed to four studies (Grube 2007;
Kosuwon 2010; Wang 2012; Widrig 2007) in which the herbal
products and placebo or active controls could not be distinguished
by colour, size, smell, shape, packaging or treatment regimen.
In some studies, descriptions of blinding were not explicit but
reference was made to compliance with relevant legislation that
mandates blinding (see Other potential sources of bias), therefore
we acknowleged that these studies also had low risk of bias.
In one study (Soltanian 2010), the method of blinding was
inadequately described and no reference was made to governing
guidelines. This study was classified as having an unclear risk of
performance and detection bias. Two studies of stinging nettle
were judged as having unclear risk despite reporting a complete
description of the double-blinding method because we considered
that placebo validity and blinding may be compromised by stinging
side eAects of this intervention (Randall 2000; Randall 2008).
Although we considered it highly likely that these studies were
suAiciently blinded, we have judged the risk of blinding as unclear.
Risk of bias has been judged as high in studies that were open
label, single blinded, or where interventions could be clearly
distinguished.
In some studies where allocation concealment was inadequately
described (see Allocation (selection bias)), it was unclear whether
clinical examiners were blinded to treatment (detection bias). We
have classified these studies as having unclear risk of bias in
blinding of the outcome assessor.
Incomplete outcome data
Low risk of bias has been attributed to three studies in
which participant withdrawals were fully reported and anayses
conducted according to an intention-to-treat model (Grube 2007;
Wang 2012; Widrig 2007). In these studies the methods for
replacing missing data were fully reported. Unclear risk of attrition
bias has been attributed to three studies in which withdrawals
were reported but not considered in the anyalses (per protocol
analysis only) (Kosuwon 2010; Randall 2000; Randall 2008). One
study reported no participant withdrawals and no missing data
(Soltanian 2010) and has been classified as having a low risk of
bias for this criterion because in this case a per protocol analysis
and intention-to-treat analysis should be identical. Studies that
neither reported participant withdrawals nor applied any method
for replacement of missing data were ascribed as at high risk of
attrition bias.
Selective reporting
Low risk of bias has been attributed to three studies that use a
confirmatory design; reported statistical power, eAect, and sample
size calculations; and provided results data in suAicient detail
to allow extraction for re-analysis (Kosuwon 2010; Wang 2012;
Widrig 2007). We have downgraded to unclear risk of reporting
bias three studies that used either exploratory designs with small
sample sizes (underpowered) (Randall 2008; Soltanian 2010) or
where some data were insuAiciently reported to allow extraction for
re-analysis (Grube 2007). Examples of selective reporting include
providing mean scores only (omission of standard deviations) at
some or all time points. Similarly, data reported only as group
change scores, percentages, or raw scores without measures of
data spread, and data presented in graphical form only, were
inadequate for re-analysis. One study was particularly poorly
reported and has been classified as having high risk of bias for
reporting (Randall 2000).
Other potential sources of bias
Selection bias due to diagnostic criteria (see Allocation (selection
bias)) is reported under the heading 'other bias' in the risk of bias
tables.
We attributed low risk of bias to studies that recruited and assessed
participants consistent with the ACR or EULAR criteria, obtained
ethics committee approval, with clinical trials registration, used
validated outcome measures, and reported compliance with the
Declaration of Helsinki and ICH GCP guidelines. Further, we
considered that risk of bias could be assumed to be low if
satisfying one of these conditions implied satisfaction of another.
For example, the ICH GCP guidelines were recommended in
Germany, France, Great Britain and Scandanavia from 1986
onwards, therefore we have assumed that Human Research
Ethics Committee approvals granted for studies aNer this time in
these countries necessitated compliance with these guidelines. In
1989, these guidelines were recommended across the European
Community (EC) as then constituted. Again, we have assumed
that from this date studies conducted in EC countries with
ethics committee approval have complied with the guidelines
regarding randomisation, allocation concealment, and blinding of
participants and assessors.
In 1996, compliance with ICH CGP guidelines was required
under German law governing clinical trials. The ICH GCP
guidelines are now adopted by the WHO and most countries,
including many developing countries, are listed as following
these guidelines. Formally constituted Human Research Ethics
Committees are charged with ensuring that clinical trials are
conducted in compliance with these guidelines and associated
regional legislation. We have classfied as low risk all studies that
reported either compliance with ICH GCP guidelines or ethics
committee approval, or both (Grube 2007; Kosuwon 2010; Randall
2008; Soltanian 2010; Wang 2012; Widrig 2007). High risk of bias
has been attributed to the one study that did not report any form
of ethical oversight of compliance with research design guidelines
(ICH GCP guidelines or Delaration of Helsinki) (Randall 2000).
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E>ects of interventions
See: Summary of findings for the main comparison Arnica versus
ibuprofen for osteoarthritis of the hand; Summary of findings 2
Capsicum for osteoarthritis of the knee; Summary of findings 3
Comfrey for osteoarthritis of the knee
See: Characteristics of included studies; Additional tables Table 3:
Herbal medicinal products used for the treatment of OA.
Single source medicinal plant therapies investigated in studies
of confirmatory study design were Capsicum (Kosuwon 2010),
comfrey (Grube 2007), and Arnica (Widrig 2007). Results in two
studies favoured the herbal interventions over placebo. The other
study was a head-to-head comparison of a herbal intervention with
an active control. Two studies of exploratory design investigated
topical stinging nettle (Randall 2000; Randall 2008). These studies
were conducted by the same team of researchers and reported
results favouring the intervention, but only one study included
suAicient numerical data suitable for extraction. Because of the
stinging sensation produced by this intervention, neither study
achieved adequate blinding. The single study of Marhame-Mafasel
did not include complete details of the herbal product suAicient
to replicate the study (Soltanian 2010). The same was true for
the study of Chinese herbal patches (FNZG and SJG), however
these products are priorietary and replication of these studies
(multiple comparisons in one report) may be possible if the
products were prepared according to manufacturing standards
(Wang 2012). Results of all comparisons of interventions against
placebo and head-to-head comparisons are reported for interest
and completeness. No serious side eAects were observed with any
topical medicinal plant product.
Arnica montana (Arnica)
Three times daily topical application of a gel containing a tincture
ofArnica montana was compared with a gel containing ibuprofen
in 204 patients (174 participants per protocol) with OA of the
hands over three weeks (Widrig 2007). Hand pain measured using
a 100 mm VAS, hand function, 28 tender joint count, and duration
and intensity of morning stiAness were not significantly diAerent
between groups, either as final end point measures or as changes
from baseline scores. Mean cumulative doses of rescue medication
(acetaminophen) diAered only by 25 mg (MD 25, 95% CI 1066.47
to 1016.47; Analysis 1.6) over the intervention period. The number
of participants reporting adverse events was similarly consistent
between the two groups (odds ratio (OR) 1.75, 95% CI 0.70 to 4.37, P
= 0.23; Analysis 1.7). These results suggested that short term topical
use of Arnica gel aAorded not inferior eAects to those of ibuprofen
gel, consistent with the research hypothesis. No comparison of
Arnica gel to placebo was identified in this systematic review of the
literature.
Capsicum species
In 99 patients studied over four weeks, three times daily application
of a gel containing a tincture of Capsicum species was superior to
placebo in reducing osteoarthritic knee pain measured using a 100
mm VAS (MD -1.00, 95% CI -6.76 to 4.76; Analysis 2.1) and overall
OA measured using the composite WOMAC score (MD -2.64, 95% CI
-9.51 to 4.23; Analysis 2.2). On both these measures the eAect sizes
were small and CIs crossed the midline indicating that Capsicum
was not markedly better than placebo.
FiNy-seven participants reported a burning sensation in the skin
during treatment with Capsicum extract gel but no participants
withdrew from the study for this reason. Burning is a known side
eAect of Capsicum, associated with the mechanism of action of
this medicinal plant, and may not be suAicently problematic to be
classified as 'adverse', however when burning was included as an
adverse event, the risk ratio of experiencing an adverse event while
using Capsicum gel rather than placebo was 4.12 (95% CI 3.30 to
5.15; Analysis 2.3).
Symphytum oicinale (comfrey)
In a large (n = 220) parallel group trial, three times daily topical
use of an ointment containing comfrey root (Symphyti o ic. radix)
was compared with placebo over three weeks of intervention
(Grube 2007). Grube 2007 found that treatment with comfrey root
resulted in statistically significant improvements on the 100 mm
VAS measures of total pain, pain at rest, and pain on movement;
and on WOMAC scores of pain, stiAness, physical function and
overall score. Data from this study could not be extracted for
further analysis because the trial authors reported neither absolute
scores nor measures of data spread (standard deviations, CIs)
for any outcomes (Grube 2007). Mean within-group changes from
baseline in pain at rest, pain on movement, WOMAC pain, stiAness,
physical function and total scores, and SF-36 physical and mental
component summary scores, are reported here for descriptive
comparison (see Analysis 3.3 to Analysis 3.10).
Urtica dioica (stinging nettle)
Seven days of topical application of one stinging nettle leaf (freshly
cut once a day and then applied directly to the painful area
with gentle pressure and leaf movement) was compared with
placebo (white dead nettle) for base of thumb pain (Randall
2000). This study was of limited use because the diagnosis of OA,
although likely, was not established at baseline using ACR or EULAR
criteria. This study was a crossover trial with two single weeks of
intervention, each preceded by five weeks of washout. Randall 2000
reported that one week of treatment with stinging nettle aAorded
statistically significant improvements in pain measured using a 100
mm VAS (P = 0.026) and disability measured using the Stanford
Health Assessment Questionnaire Disability Index (HAQ-DI, P =
0.003) over placebo. Data reported in this study were presented per
intervention rather than providing divided data for each stage of the
crossover, and were insuAicient to allow extraction for re-analysis.
A follow-up study by the same author team was a one week
comparison of stinging nettle leaf against another Urtica species.
This study included 16 weeks of follow-up. In between-group
comparisons for pain at one week post-treatment (Analysis 5.1),
and stiAness (Analysis 5.2) and physical function (Analysis 5.3) at
four weeks post-treatment, stinging nettle was not significantly
diAerent to placebo. Because the stinging nettle group showed
a greater within-group improvement in pain at one week post-
treatment, the authors argued in favour of this treatment, however
we noted that the stinging nettle group commenced the study with
a greater mean pain score at baseline, so improvement in this group
was not hampered by a floor eAect.
Herbal mixture (Marhame-Mafasel)
A pomade of herbs known as Marhame-Mafasel was compared
against placebo in a crossover study of 42 participants with OA of
the knee. This study comprised two intervention periods of three
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weeks each. No washout period occured between the intervention
periods but this weakness in study design was accounted for in this
review because we have extracted data from the first intervention
period only (up to crossover). These results showed small eAects for
Marhame-Mafasel over placebo for improvements in pain (Analysis
4.1), physical function (Analysis 4.3), knee stiAness (Analysis 4.2)
and overall disease severity (composite WOMAC score; Analysis 4.4).
Although the authors reported a large and statistically significant
omnibus eAect for treatment (mean eAect 3.94, SD 2.01), none of
the univariate eAect sizes appeared to be statistcally significant
or clinically meaningful (minimal clinically important diAerence
(MCID) not reported).
Further, although the authors reported no dropouts or withdrawals
from the study, we question the meaningfulness of this claim
because compliance with the intervention was low: "A patient
was considered to comply with the assigned treatment if more
than 75% of the pomade in the tubes was taken and moderate
compliance if 25% to 75% of the pomade in the tubes was
taken". Participants who used less than 25% of the pomade
were classified as having poorly complied with the intervention,
yet data from these participants were included unaltered in the
study. It was possible that this classification of compliance was
created post hoc as a stategy to include all data. We suggest
that monitoring throughout the study and exclusion of non-
complying participants, with replacement of missing data via the
last observation carried forward method, would have been more
robust and meaningful. Alternately, a post hoc multivariate analysis
could have been undertaken to determine any confounding eAect
of poor participant compliance.
Chinese herbal patches
Chinese herbal patches containing either Fufang Nanxing Zhitong
Gao (FNZG) or Shangshi Jietong Gao (SJG) were compared to
placebo in a three-arm trial of 150 participants with OA of the
knee. The intervention was maintained for seven days. The results
showed modest eAects in favour of both Chinese herbal patches
over placebo, with eAects being slightly larger in the FNZG group.
Although the study was of a confirmatory design with suAicient
power (80%) to detect changes, none of the eAects were statistically
significant.
Participants in the FNZG patch group rated their pain on walking
(Analysis 6.1), pain due to OA (Analysis 6.2), and physical function
(Analysis 6.4) as improved, compared with participants who used
the placebo patches, but they also reported more adverse side
eAects (Analysis 6.6), notably skin irritation. Results were noted in a
similar direction but with smaller eAect sizes for SJG patches over
placebo for pain on walking (Analysis 7.1), pain due to OA (Analysis
7.2), and physical function (Analysis 7.4); as well as similar rates of
side eAects (Analysis 7.6). A head-to-head comparison of the two
patches was equivocal. No participants reported adverse eAects
from using the placebo patches.
D I S C U S S I O N
Summary of main results
One confirmatory study is available for products from Arnica
montana (Widrig 2007) (Summary of findings for the main
comparison), Capsicum species (Kosuwon 2010) (Summary of
findings 2), Symphytum o icinale (Grube 2007) (Summary of
findings 3), and two Chinese herbal patches (Wang 2012) (Table
4; Table 5; Table 6). Moderate quality evidence from one trial
(174 participants) indicates that Arnica montana is equivalent to
topical ibuprofen in terms of pain relief and improvement of hand
function. We are less certain about the incidence of adverse events,
which may be of concern with both topical Arnica extract and
ibuprofen gel. Moderate evidence from one trial (99 participants)
shows that topical Capsicum extract may possibly improve pain
and overall function in people with osteoarthritis (OA) of the knee,
but improvements are inconsistent (confidence intervals cross
the midline) and some people may experience adverse eAects,
particularly skin irritation and burning.
Moderate evidence from one trial (150 participants) shows that
patches containing two diAerent formulations of Chinese herbs
may possibly improve pain and function in people with OA of
the knee, but the interventions were tested over seven days
only, which may be insuAicient for making judgements about
clinical importance. We are uncertain about the clinical application
of this evidence but the trial was quite well designed (double
blind, randomised, controlled), thus we have graded the evidence
for Chinese herbal patches as moderate but we have presented
the summary of findings tables for these interventions under
additional tables.
One exploratory study of the herbal mixture Marhame-Mafasel (42
particpants) identified a possible trend of eAectiveness (confidence
interval cross midline) that needs to be investigated in further
rigorous trials (Soltanian 2010) (Table 7). Two pilot studies of topical
nettle leaf returned disparate results; one study (crossover design)
identified a trend for eAectiveness (Randall 2000) (Table 8) but
the follow-up study (parallel groups) returned equivocal results on
between-group comparisons (Randall 2008) (Table 9). Both these
studies were hampered by design flaws.
Overall completeness and applicability of evidence
The mechanism of action provides a rationale for topical
medicinal plant products from Arnica montana, Capsicum species,
Symphytum o icinale and Urtica dioica as alternative options for
the treatment of OA complaints. However, for the herbal mixtures
the mechanism of action is less well ellucidated through in vitro
studies, and the rationale for their use is unclear.
For none of the products is the quality or quantity of current
scientific evidence of eAectiveness suAicient. There is, at best,
moderate evidence to support the use of Arnica, Capsicum and
comfrey. However, for each of these interventions, further high
quality clinical trials are likely to have an important impact on our
confidence in the estimate of eAect and may change the estimate.
To be more confident in our estimates of clinical eAectiveness
we require well designed, randomised, double blind studies of a
confirmatory study design with adequate power and sample size (n
> 400) that test interventions over clinically relevant durations.
The results of studies undertaken with a proprietary product
cannot be transferred to any preparation of the medicinal
plant part (Chrubasik 2003). If the starting material and
manufacturing process of products diAer, active principles will
diAer and thus the sum of all actions of the ingredients.
Due to insuAicient declaration, the studies undertaken with
Arnica, Capsicum, comfrey, and the herbal mixtures FNZG, SJG
and Marhame-Mafasel are not repeatable unless the products
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can be obtained from the producer or the laboratory. Even if
these products can be obtained, due consideration must be
given to the guidelines of Good Manufacturing Practice (GMP)
and Good Distribution Practice (GDP); these guidelines ensure
that medicinal plant products are consistently produced and
controlled to the quality standards appropriate to their intended
use, and that the level of quality determined by the GMP
and the properties of the products are maintained throughout
the distribution (www.ema.europa.eu/ema/index.jsp?curl=pages/
regulation/document_listing/
document_listing_000154.jsp&mid=WC0b01ac0580027088&jsenabled=tru,
www.who.int/vaccines-documents/DocsPDF/www9666.pdf).
It is a common but erroneous assumption that medicinal plant
products are safer than other therapies for OA. All topical herbal
medicinal products for the treatment of OA, except preparations
from Capsicum species, have a low risk of adverse events when
used in the suggested doses (Table 1; Table 2). Minor adverse
reactions occurred with all medicinal plant treatments identified
in this review, and only in the case of comfrey were these events
more commonly reported among the placebo group (Analysis 3.11).
Allergic reactions may occur with any of the topical medicinal
plant products (ESCOP 2003; ESCOP 2009), but Capsicum species,
comfrey and Arnica also contain toxic ingredients. Capsaicin
is neurotoxic (Anonymous 2007; Nolano 1999) and a potential
carcinogen (in animal and in vitro studies) (Anonymous 2007).
The alkaloids in comfrey are hepatotoxic and carcinogenic (Li
2011). In vitro studies of Arnica raise concerns of cytotoxicity
(Woerdenbag 1994). Because of the risk of cytotoxicity, comfrey
and Arnica are recommended for external use only (ESCOP 2003;
ESCOP 2009). In contrast to the other medicinal plant preparations,
use of capsaicinoid containing preparations is restricted up to
several weeks (ESCOP 2009) and the content of toxic alkaloid in the
daily dose of topical comfrey has been limited to 100 µg per day
(Blumenthal 1998).
Quality of the evidence
See: Characteristics of included studies, 'Risk of bias' tables.
Generally, the studies included in this review are of lower quality
than desired, but we stress that these studies represent the current
best quality evidence for the eAectiveness of topical medicinal
plant interventions in the treatment of OA.
Moderate evidence for estimate of e>ect: there is, at best,
moderate evidence for creams and gels containing Arnica, comfrey,
or Capsicum extract and Chinese herbal patches (FNZG and SJG) as
topical herbal medicines in the treatment of OA. The evidence for
these interventions is drawn from small (n < 400) single studies and
is thus downgraded to moderate. Because the patches containing
the two formulations of Chinese herbs were tested over seven
days only, which may be insuAicient for making judgements about
clinical importance, we are uncertain about the clinical application
of this evidence. We have graded the evidence for Chinese herbal
patches as moderate but have presented the summary of findings
table for these interventions under additional tables (Table 4; Table
5; Table 6).
Low evidence for estimate of e>ect: one exploratory study of
the herbal mixture Marhame-Mafasel (42 particpants) identified a
possible trend of eAectiveness (confidence intervals cross midline)
that needs to be investigated in further rigorous trials (Soltanian
2010) (Table 7).
Very low evidence for estimate of e>ect: two pilot studies of
topical nettle leaf returned disparate results; one study (crossover
design) identified a trend of eAectiveness (Randall 2000) (Table
8) but the follow-up study (parallel groups) returned equivocal
results on between-group comparisons (Randall 2008) (Table 9).
Both these studies were hampered by design flaws.
Poorer quality studies using non-randomised, uncontrolled
designs were excluded (for example Linsheng 1997). Similarly, we
excluded clinical trials of products that are not strictly herbal
so as to avoid misinterpretation of the results of these studies
in herbal medicine practice (for example Altman 1994; Gemmell
2003). We note that more recent studies are typically of higher
quality than older studies and commend researchers in this field for
the improvement in research design and reporting.
Potential biases in the review process
This review is compromised by some poorly designed clinical trials
that are underpowered and inadequately blinded. Herbal medicine
is not a field known for the widespread adoption of evidence-based
practice, however, in light of the small and low quality body of
evidence in topical herbal treatment for OA, it is unsurprising that
practitioners might continue to ignore the research and do what
they 'have always done'. In this section, therefore, we have chosen
to address some of the common biases in herbal medicine as well
as in this review.
Agreements and disagreements with other studies or
reviews
Evidence for topical capsaicin in the relief of osteoarthritic pain
has previously been described as promising (Cameron 2007;
Cameron 2009; Little 2000); however, because extracts reduced
to single compounds are not herbal interventions according to
the strictest WHO definitition, studies investigating the single
extracted ingredient capsaicin were excluded from this review.
The one study of an extract from Capsicum fruits that was
included in this review showed small beneficial eAects of the
intervention, but not significantly greater than with placebo
(Analysis 2.1; Analysis 2.2; Summary of findings 2). Favourable
eAects identified in the excluded studies (Altman 1994; Deal 1991;
McCarthy 1992; McCleane 2000; Schnitzer 1994) are generally larger
but are attributed to higher doses of capsaicin (0.025 to 0.05%
v.v. in a vehicle cream) than the dose used in the included study
(0.0125%). Even at the lower dose, the extract of Capsicum species
is associated with a substantive risk of skin irritation (RR 4.12, 95%
CI 11.61 to 24.84).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The current available evidence for topical herbal treatment of
osteoarthritis (OA) is sparse and it is diAicult to give clear
recommendations regarding use of these products. Generally, high
tolerance of the herbal medicinal products was demonstrated;
however, caution is warranted in interpreting safety due to the
small sample size in some of the studies. Accepting that there
are few high quality randomised controlled trials of the eAicacy
or safety of topical medicinal plant products, in the absence of
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more robust results we recommend that practitioners adopt the
preparations, methods of administration, and doses of topical
products suggested in the monographs (see Background).
The only recommendations we are confident to make for clinical
practice are that a) Arnica gel probably improves pain and function
as eAectively as a gel containing non-steroidal anti-inflammatory
drug, but with no better (and possibly worse) adverse event profile;
and b) comfrey extract gel probably improves pain more than
placebo. EAects of comfrey gel on physical function and quality of
life in people with OA are not estimable from the data provided.
Capsicum extract gel probably will not improve pain or function
more than placebo at the dose examined in this review. Although
patches containing the Chinese herbal mixtures FNZG and SJG
probably slightly improve pain and function more than placebo, we
are uncertain of the clinical applicability of these results because
these interventions were tested over seven days only. There is
insuAicient evidence to make clinical recommendations for or
against the use of other topical herbal medicines for the treatment
of OA.
Implications for research
We recommend that future updates of this review focus on the
topical herbal interventions for which there currently appears to
be moderate evidence, Arnica, Capsicum, comfrey, and the Chinese
herbal mixtures FNZG and SJG.
At this stage we cannot recommend that resources be invested
in single small studies of untested herbal interventions or herbal
interventions for which the current evidence is low or very low.
Such studies do not add substantially to the body of evidence but
increase confusion among practitioners.
Several studies were excluded from this review on the grounds
that they did not investigate truly herbal products. Included
studies are hampered by flawed research design, including unclear
recruitment criteria, and inadequate characterisation of the herbal
interventions. Other studies are of limited usefulness because
the selection criteria were incomplete, methods were confusingly
reported (Begg 1996; Moher 2001), or data were presented to
support the authors' preferred conclusions (McGauran 2010). We
recommend that future researchers give attention to the detail of
study design, ensuring that participant samples are well defined
according to ACR and EULAR criteria and recruited without bias,
that herbal preparations are reported in detail, including dose,
extraction method and active principle, and that study results are
recorded using reliable, valid outcome measures.
Evidence for mechanisms of eAect and toxicity are drawn from
animal studies and in vitro designs rather than from human clinical
trials. Well designed, fully powered clinical trials are required to
confirm the eAicacy of most topical medicinal plant products in
humans. We encourage herbal medicine practitioners to consider
involvement of themselves, their practices, and their patients in
future clinical trials to ensure that representative patient groups are
included and that trial results have broad applicability to everyday
practice.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Randomised, double-blind, placebo control, 2 parallel groups, 2 centre study. Duration 3 weeks.
Participants Randomised n=220, Completed n=186. Mean age 58 years. M:F 67:153. Inclusion: OA knee (criteria not
specified), pain VAS 0-100 >40mm.
Interventions Kytta-Salbe® f: Symphytum officinale radix (comfrey root) extract, 6g (2g TID), ointment.
Placebo control: ingredients not reported, ointment.
Regimen: If bilateral OA, treat both knees, but outcome measures limited to most painful joint only.
Massage 6cm long thread of ointment into skin covering the knee three times daily.
Outcomes Pain at rest VAS 0-100, pain with movement VAS 0-100, WOMAC-VAS 0-100 (24 items, 3 subscales; all VAS
0 indicates no deficits, 100 indicates worst possible deficits).
Notes Results favour intervention.
Risk of bias
Grube 2007 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised, method not reported1. Baseline parameters com-
pared for significant differences.
Allocation concealment
(selection bias)
Low risk Allocation concealment not reported1.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention and placebo not distinguished
by look, taste, smell or packaging.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals.
Included full analyses (intention-to-treat) and valid case analyses (per-proto-
col).
Selective reporting (re-
porting bias)
Unclear risk Confirmatory design, large sample size, statistical power not reported, alpha
0.05. (low risk)
Most outcome data reported as change scores, percentages, and graphs only,
insufficient for extraction. (unclear risk)
Standard deviations for pain estimated from graphical data.
Reported adverse events. (low risk)
Other bias Unclear risk Criteria for diagnosis of OA not specified at baseline. Diagnosis not consistent
with ACR criteria, but likely to be OA. (unclear risk)
Reported compliance with Declaration of Helsinki and ICH GCP guidelines.
(low risk)
Grube 2007  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 group, crossover study. Duration 4 weeks each arm, 1
week washout.
Participants Randomised n=100, Completed n=99. Mean age 61 years, range 44-82 years. M:F = 100:0. Inclusion: OA
knee (ACR criteria).
Interventions Capsika gel: Capsicum (species not stated) extract.
Placebo control: ingredients not reported.
Regimen: TID, applied 2 inches of extruded gel around the knee and rubbed in until dry.
Rescure mediccation permitted: paracetamol (acetaminophen) up to 1500mg (3 x 500mg).
Outcomes Pain VAS 0-100 (0 indicates no pain, 100 indicates worst possible pain), WOMAC 0-4 (24 items, 3 sub-
scales, higher scores indicate worse deficits).
Notes Results favour intervention.
Risk of bias
Bias Authors' judgement Support for judgement
Kosuwon 2010 
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Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Described as double-blind. Active intervention, placebo, and active controls
not distinguished by look, taste, smell, packaging, or medication regimen.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals. (low risk)
Per protocol analysis only. (unclear risk)
Selective reporting (re-
porting bias)
Low risk Confirmatory design, sample size slightly smaller than planned, statistical
power 80%, alpha 0.05.
Outcome VAS 0-10 converted to 100mm scale for data extraction.
Reported adverse events.
Other bias Low risk Diagnosis / assessment consistent with ACR criteria.
Reported ethics committee approval.
Reported clinical trials registration (IDNCT00471055).
Reported financial and in kind support.
Kosuwon 2010  (Continued)
 
 
Methods Randomised, double-blind, placebo control, 2 group crossover. Duration 12 weeks (2 x 1 week interven-
tion, each followed by 5 week washout).
Participants Randomised n=27, Completed n=24. Mean age 60 yrs, range 45-82 yrs. M:F 4:23. Inclusion: persistent
base of thumb pain (OA criteria not specified).
Interventions Tradename not provided.Urtica dioica (stinging nettle).
Placebo control: Lamium album (white dead nettle).
Regimen: Whole leaf plucked from live plant, applied directly to skin of painful thumb, total contact
with skin 30 seconds per day.
Outcomes Pain VAS 0-100 (0 indicates no pain, 100 indicates worst possible pain), pain (verbal 5 point scale, 0 in-
dicates no pain, 5 indicates worst possible pain), HAQ-DI (higher score indicates more disability), anal-
gesics, NSAID use, and sleep (scales not reported).
Notes Results favour intervention, but mean improvement in HAQ-DI score does not exceed accepted minimal
clinically important difference.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported.
Randall 2000 
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Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Active intervention and placebo not distinguished by look, taste, or smell, but
placebo validity and blinding may be compromised by stinging effect of active
intervention.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals. (low risk)
Per protocol analysis only. (unclear risk)
Selective reporting (re-
porting bias)
High risk Exploratory study design; power, effect, and sample size not determined a pri-
ori. (unclear risk)
Reported adverse events. (low risk)
Included notes on unsatisfactory outcome measures. Most outcome data were
reported as means only (not standard deviations) without confidence inter-
vals. (unclear risk)
Data for first and second periods were aggregated and insufficient for extrac-
tion from the first arm (up to crossover) only. (high risk)
Aggregated data were extracted for the critical outcome of pain for inclusion in
the summary of findings tables. An error was identified during this data extrac-
tion. (unclear risk)
Other bias High risk Criteria for diagnosis of OA not specified at baseline. Other arthritides are pos-
sible confounders. (high risk)
Did not report ethical oversight.
Randall 2000  (Continued)
 
 
Methods Randomised, single blind, placebo control, 2 parallel groups. Duration 1 week intervention, plus 15
weeks follow-up.
Participants Randomised n=42, Completed intervention n=42, Completed follow up n=35. Mean age intervention
group 65 yrs, control 67 yrs. M:F control 13:8, intervention 11:10. Inclusion: presumptive diagnosis
of knee OA based on ACR criteria (Read diagnositic code/s for "knee pain" or "OA knee" in clinical
records), aged 55-80 yrs, knee pain most days of the previous month, WOMAC pain subscale score of at
least 4 at baseline.
Interventions Tradename not provided. Urtica dioica (stinging nettle).
Placebo control: Urtica galeopsifolia (non-stinging nettle).
Regimen: Whole leaf plucked from live plant, applied directly to skin of painful knee, total contact with
knee 1 minute per day.
Outcomes WOMAC 0-4 (A, B, and C subscales; 24 items, 3 subscales, higher scores indicate worse deficits), pain
at rest VAS 0-100, pain on walking VAS 0-100 (all VAS 0 indicates no pain, 100 indicates worst possible
pain), patient global assessment of beneficial and adverse reactions, medication diary (scales not re-
ported).
Qualitative outcomes: focus groups discussions to explore participants' attitudes and experiences of
the trial.
Randall 2008 
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Notes Results equivocal; stinging nettle not superior to placebo. Outcome scores for participants who re-
turned poorly kept nettle plants did not differ significantly from group means.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated, block randomisation.
Allocation concealment
(selection bias)
Low risk Adequate allocation concealment can be inferred. "Plants in serially num-
bered, opaque pots."
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Active intervention and placebo not distinguished by look, taste, or smell, but
placebo validity and blinding may be compromised by stinging effect of active
intervention.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Reported withdrawals. (low risk)
Per protocol analysis only. (unclear risk)
Selective reporting (re-
porting bias)
Unclear risk Exploratory study design; power, effect, and sample size not determined a pri-
ori. (unclear risk)
Reported adverse events. (low risk)
Other bias Unclear risk Diagnosis not consistent with ACR criteria. OA not distinguished from other
causes of knee pain in older adults at baseline (presumptive diagnosis). Al-
though OA is the most likely cause of knee pain in older adults, other arthri-
tides are possible confounders. (unclear risk)
Reported ethics committee approval. (low risk)
Randall 2008  (Continued)
 
 
Methods Randomised, placebo control, double blind, single centre, crossover. Duration 6 weeks (2 x 3 week in-
tervention, no washout).
Participants Randomised n=42; intervention n=21, control n=21. Completed n=42; intervention n=21, control n=21.
OA knee (EULAR criteria).
Interventions Marhame-Mafasel: Arnebia euchroma and Matricaria chamomilla pomade.
Placebo control: ingredients not reported, pomade.
Regimen: 4.5g/day (1.5g TID) of pomade massaged firmly into skin until completely disappeared.
Outcomes WOMAC VAS 0-100 (24 items, 3 subscales, higher scores indicate worse deficits).
Notes Results favour intervention. In all between and within-group comparisons, improvements in os-
teoarthritic pain, function, and stiffness were greater in people using Marhame-Mafasel over placebo.
Improvement scores attributed to Marhame-Mafasel were somewhat greater in the second arm of the
crossover, suggesting that there may be a concurrent benefit from vigorous massage over time.
Risk of bias
Soltanian 2010 
Topical herbal therapies for treating osteoarthritis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
30
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised. "Randomized according to a random number ta-
ble."
Allocation concealment
(selection bias)
Unclear risk Allocation concealment not reported.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Described as double blind. Active interventions not distinguished by look,
taste, smell or packaging. (low risk)
Blinding of assessors not reported. (unclear risk)
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported no missing data, no withdrawals, no participants lost to follow up.
(low risk)
Per protocol analysis only. (low risk if no missing data)
Selective reporting (re-
porting bias)
Unclear risk Exploratory study design; power, effect, and sample size not determined a pri-
ori. (unclear risk)
Reported adverse events. (low risk)
Other bias Low risk Diagnosis / assessment consistent with ACR crtieria. (low risk)
Reported ethics committee approval. (low risk)
Reported that not all participants "completed" the intervention and that some
participants displayed poor compliance with the intervention, but it is unclear
how lack of compliance influenced results.
Soltanian 2010  (Continued)
 
 
Methods Randomised, placebo control, double blind, single centre, 3 parallel groups (2 interventions). Duration
7 days.
Participants Randomised n=150; intervention A n=60, intervention B n=60, control n=30. Completed n=42; interven-
tion n=21, control n=21. OA knee (Chinese Orthopaedic Association criteria), baseline pain >20mm on
100mm VAS.
Interventions Intervention A: topical patch containing Fufang Nanxing Zhitong Gao (FNZG) Chinese herbal mixture.
Intervention B: topical patch containing Shangshi Jietong Gao (SJG) Chinese herbal mixture.
Placebo control: topical patch made of acrylic, adhesive tape (no ingredients).
All patches applied to skin of right or leN knee for 8 hours per day (overnight).
Outcomes Pain VAS 0-100, WOMAC, Traditional Chinese Medicine Syndrome Questionnaire (TCMSQ).
Notes Results favour FNZG patches.
Risk of bias
Bias Authors' judgement Support for judgement
Wang 2012 
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Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, method not reported.
Allocation concealment
(selection bias)
Unclear risk Allocation reported as concealed, method not reported.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Active interventions and placebo control not distinguished by look, taste,
smell or packaging.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals.
Included per protocol and intention-to-treat analyses.
Missing data replaced using last observation carried forward method.
Selective reporting (re-
porting bias)
Low risk Confirmatory design, statistical power 80%, alpha 0.05.
All data reported as means and confidence intervals. Standard deviations cal-
culated during data extraction.
Reported adverse events.
Other bias Low risk Diagnosis and assessment consistent with ACR criteria.
Reported eithics committee approval, and clinical trials registration.
Wang 2012  (Continued)
 
 
Methods Randomised, double blind, active control (ibuprofen 5% topical gel), 2 parallel groups, 20 centre study.
Duration 3 weeks.
Participants Randomised n=204, Completed n=174. Mean age 64 yrs. M:F 57:147. Inclusion: OA hand (ACR criteria).
Interventions A. Vogel Arnica Gel: Arnica montana (mountain arnica), tincture 50% v v.
Outcomes Pain VAS 0-100 (0 indicates no pain, 100 indicates worst possible pain), hand algofunctional index 0-3
(10 items, higher score indicates worse function), tender joint count, morning stiffness intensity and
duration, patient evaluation of efficacy, patient acceptance of treatment, physician evaluation of effi-
cacy, acetaminophen use.
Notes Arnica equally effective as ibuprofen on all primary and secondary measures. Post-intervention pain
scores high with large standard deviation in both groups.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Described as randomised, method not reported1.
Allocation concealment
(selection bias)
Low risk Allocation concealment not reported1.
Blinding (performance
bias and detection bias) 
Low risk Active interventions not distinguished by look, taste, smell or packaging.
Widrig 2007 
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All outcomes
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported withdrawals. Included per protocol and intention-to-treat analyses.
Selective reporting (re-
porting bias)
Low risk Confirmatory design, statistical power 80%, alpha 0.024.
Reported adverse events.
Non-inferiority hypothesis, MCID determined a priori at 12%.
Other bias Low risk Diagnosis / assessment consistent with ACR criteria.
Reported eithics committee approval, and complince with ICH GCP guidelines
and Declaration of Helsinki.
Widrig 2007  (Continued)
Unless otherwise stated, all oral medications are reported as total daily doses, which may have been administered in single or divided
doses.
Unless subscales are named, outcome measures (eg: WOMAC, HAQ, COAT) were used in entirety. Unless specified, all outcome measures
were administered, scored, and scaled according to OARSI standards.
1. Reported compliance with ICH GCP guidelines (ICH 2004) anchored in European law, so adequate randomisation, allocation
concealment, and blinding can be assumed.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Altman 1994 Intervention included extracted capsaicin, therefore not herbal as per WHO definition.
Deal 1991 Intervention included extracted capsaicin, therefore not herbal as per WHO definition.
Gemmell 2003 Intervention included capsaicin and menthol (extracted or synthetic), therefore not herbal as per
WHO definition. Ingredients not listed in sufficient detail, therefore study is only repeatable using
the proprietary product.
Kielczynski 1997 Discussion paper.
Linsheng 1997 Not a randomised controlled trial. Case series.
Long 2001 Review paper.
McCarthy 1992 Intervention included extracted capsaicin, therefore not herbal as per WHO definition.
McCleane 2000 Intervention included extracted capsaicin, therefore not herbal as per WHO definition.
McKay 2003 Intervention included capsaicin and menthol (extracted or synthetic), therefore not herbal as per
WHO definition. Ingredients not listed in sufficient detail, therefore study is only repeatable using
the proprietary product.
Rayburn 2009 Not a randomised controlled trial.
Sagar 1988 Not a randomised controlled trial.
Saley 1987 Not a randomised controlled trial. Case series.
Schnitzer 1994 Intervention included extracted capsaicin, therefore not herbal as per WHO definition.
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Study Reason for exclusion
Smith 2011 Intervention included tannic acid (extracted or synthetic), therefore not herbal as per WHO defini-
tion.
Wadnap 2006 Not a randomised controlled trial (observational study).
Yuelong 2011 Not a randomised controlled trial. Protocol for a randomised controlled trial only.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods RCT
Participants n=92
Interventions Intervention: herbal ointment containing cinnamon, ginger, mastic (Saghez) and sesame oil.
Active control: salicylate ointment.
Outcomes Pain VAS 0-100, stiffness VAS 0-100, limited motion VAS 0-100.
Notes Head to head comparison, non-inferiority hypothesis.
Abstract only available. Pakistan Journal of Biological Science is not indexed. Full manuscript
sought in hard copy via inter-library loan.
Zahmatkash 2011 
 
 
Methods RCT
Participants n=88 (intervention n=44, control n=44)
Interventions Intervention: Bushen Quhan Tongluo herbs by orally or externally washing.
Bushen Quhan. Tongluo: Hutaorou (12 g), Buguzhi (12 g), Chaoduzhong (12 g), Shudi (15 g), Dahuix-
iang (9 g), Luoshiteng (15 g), Zhichuanwu (9 g), Sanqi (6 g), Wugong (3 g), Jixieteng (15 g). The pre-
scription for external washing: Tuogucao (40 g), Danggui (15 g), Sumu (15 g), Shengdahuang (15 g),
Shengnanxing (10 g), Ruxiang (10 g), Meyao (10 g), Bingpian (3 g). Topical administration: The med-
icine that dissolved in 500 mL of 100 degreesC boiled water was adopted to wash both knees while
the temperature down to 35 degreesC one dose upon a time and twice a day).
Patients in the control group were given sulfated glucosamine (Weiguli Capsule. Each capsule con-
tains 314 mg of sulfated glucosamine crystal, which is equal to 250 mg of sulfated glucosamine)
two capsules a time and 3 times a day as well as piroxicam (Yantong Xikang Pill) once a day and 20
mg each time. Patients in both groups were administrated for 12 weeks. 
Outcomes WOMAC
Notes Unable to distinguish oral administration internvention group from topical administration inter-
vention group results from abstract alone.
Abstract only available. Chinese Journal of Clinical Rehabilitation not indexed. Full manuscript
sought in hard copy via inter-library loan.
Zhong 2006 
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Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Rehabilitation protocol of the Traditional Chinese Medicine on patients with dyskinesia of the knee
osteoarthritis: A randomized controlled trial study in community
Methods Randomised, controlled, parallel 2-group trial.
Participants Community dwelling male and female adults aged 40-75 years, with knee OA (Chinese Orthopaedic
Association criteria); n = 722 (intervention n= 361, control n = 361).
Interventions Foundation treatment of Chinese medicinal herb washing and traditional exercises training
method, plus blood-letting puncture, acupuncture, massage, and analgesics.
Outcomes Pain, swelling, knee range of motion, muscle strength, average walking distance, stair climbing and
descent, activities of daily living, analgesic use, quality of life, safety, health economic evaluation,
global effect.
Starting date Unknown. Ethics committee approval from 27/09/2012.
Contact information Su Youxin: No. 1, HuaTuo road, Shangjie town, Minhou county, Fujian, Fuzhou, China; +86 1330 502
1666; suyouxin777@hotmail.com
Notes Prospective registration, ongoing clinical trial.
Youxin 2012 
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Arnica versus ibuprofen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 1   Mean Difference (IV, Random, 95% CI) Totals not selected
2 28 painful joint count change from
baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
3 Intensity of morning stiffness (1 to
5) change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
4 Duration of morning stiffness (1 to
5) change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
5 Hand algofunctional index (0 to
30)
1   Mean Difference (IV, Random, 95% CI) Totals not selected
6 Cumulative dose of analgesics
(acetominophen mg) over 3 weeks
1   Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Participants (n) reported adverse
events
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
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Analysis 1.1.   Comparison 1 Arnica versus ibuprofen, Outcome 1 Pain VAS 0-100.
Study or subgroup Arnica gel Ibuprofen gel Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Widrig 2007 89 40.4 (21.5) 85 44.2 (20.9) -3.8[-10.1,2.5]
Favours arnica 10050-100 -50 0 Favours ibuprofen
 
 
Analysis 1.2.   Comparison 1 Arnica versus ibuprofen, Outcome 2 28 painful joint count change from baseline.
Study or subgroup Arnica gel Ibuprofen gel Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Widrig 2007 89 -3 (4.4) 85 -2.5 (3.2) -0.5[-1.64,0.64]
Favours arnica 105-10 -5 0 Favours ibuprofen
 
 
Analysis 1.3.   Comparison 1 Arnica versus ibuprofen, Outcome
3 Intensity of morning sti>ness (1 to 5) change from baseline.
Study or subgroup Arnica gel Ibuprofen gel Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Widrig 2007 89 -0.9 (1.1) 85 -1 (0.8) 0.1[-0.18,0.38]
Favours arnica 105-10 -5 0 Favours ibuprofen
 
 
Analysis 1.4.   Comparison 1 Arnica versus ibuprofen, Outcome
4 Duration of morning sti>ness (1 to 5) change from baseline.
Study or subgroup Arnica gel Ibuprofen gel Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Widrig 2007 89 -0.9 (1.3) 85 -0.8 (1.1) -0.1[-0.46,0.26]
Favours arnica 105-10 -5 0 Favours ibuprofen
 
 
Analysis 1.5.   Comparison 1 Arnica versus ibuprofen, Outcome 5 Hand algofunctional index (0 to 30).
Study or subgroup Arnica gel Ibuprofen gel Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Widrig 2007 89 7.1 (4.8) 85 7.5 (4.3) -0.4[-1.75,0.95]
Favours arnica 2010-20 -10 0 Favours ibuprofen
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Analysis 1.6.   Comparison 1 Arnica versus ibuprofen, Outcome 6
Cumulative dose of analgesics (acetominophen mg) over 3 weeks.
Study or subgroup Arnica gel Ibuprofen gel Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI Fixed, 95% CI
Widrig 2007 89 5625 (3400) 85 5650 (3600) -25[-1066.47,1016.47]
Favours treatment 1000500-1000 -500 0 Favours control
 
 
Analysis 1.7.   Comparison 1 Arnica versus ibuprofen, Outcome 7 Participants (n) reported adverse events.
Study or subgroup Arnica gel Ibuprofen gel Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Widrig 2007 14/105 8/99 1.65[0.72,3.76]
Favours arnica 100.1 50.2 20.5 1 Favours ibuprofen
 
 
Comparison 2.   Capsaicin 0.0125% versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 1   Mean Difference (IV, Random, 95%
CI)
Totals not selected
2 WOMAC 0-4 (Overall) 1   Mean Difference (IV, Random, 95%
CI)
Totals not selected
3 Adverse event episodes (n) reported 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 2.1.   Comparison 2 Capsaicin 0.0125% versus placebo, Outcome 1 Pain VAS 0-100.
Study or subgroup Capsicum gel Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Kosuwon 2010 65 44.6 (14.6) 34 45.6 (13.5) -1[-6.76,4.76]
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 2.2.   Comparison 2 Capsaicin 0.0125% versus placebo, Outcome 2 WOMAC 0-4 (Overall).
Study or subgroup Capsicum gel Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Kosuwon 2010 65 32.2 (19.2) 34 34.8 (15) -2.64[-9.51,4.23]
Favours capsaicin 10050-100 -50 0 Favours placebo
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Analysis 2.3.   Comparison 2 Capsaicin 0.0125% versus placebo, Outcome 3 Adverse event episodes (n) reported.
Study or subgroup Capsaicin Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Kosuwon 2010 272/338 66/338 4.12[3.3,5.15]
Favours capsaicin 1000.01 100.1 1 Favours placebo
 
 
Comparison 3.   Comfrey versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain VAS 0-100 1   Mean Difference (IV, Random, 95% CI) Totals not selected
2 Pain VAS 0-100 change from
baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
3 Pain VAS 0-100 (at rest)
change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
4 Pain VAS 0-100 (movement)
change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
5 WOMAC-VAS (Pain) change
from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
6 WOMAC-VAS (Stiffness)
change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
7 WOMAC-VAS (Function)
change from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
8 WOMAC-VAS (Overall) change
from baseline
1   Mean Difference (IV, Random, 95% CI) Totals not selected
9 Change in SF-36 physical
component summary score
1   Mean Difference (IV, Random, 95% CI) Totals not selected
10 Change in SF-36 mental
component summary score
1   Mean Difference (IV, Random, 95% CI) Totals not selected
11 Participants (n) reported
adverse events
1   Risk Difference (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 3.1.   Comparison 3 Comfrey versus placebo, Outcome 1 Pain VAS 0-100.
Study or subgroup Comfrey Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Grube 2007 110 42 (28) 110 83.5 (24) -41.5[-48.39,-34.61]
Favours comfrey 10050-100 -50 0 Favours placebo
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Analysis 3.2.   Comparison 3 Comfrey versus placebo, Outcome 2 Pain VAS 0-100 change from baseline.
Study or subgroup Comfrey Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Grube 2007 110 -51.6 (0) 110 -10.1 (0) Not estimable
Favours comfrey 10050-100 -50 0 Favours placebo
 
 
Analysis 3.3.   Comparison 3 Comfrey versus placebo, Outcome 3 Pain VAS 0-100 (at rest) change from baseline.
Study or subgroup Comfrey Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Grube 2007 110 -20.9 (0) 110 -4.6 (0) Not estimable
Favours comfrey 10050-100 -50 0 Favours placebo
 
 
Analysis 3.4.   Comparison 3 Comfrey versus placebo, Outcome 4 Pain VAS 0-100 (movement) change from baseline.
Study or subgroup Comfrey Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Grube 2007 110 -30.7 (23.3) 110 -5.6 (20) -25.1[-30.84,-19.36]
Favours comfrey 10050-100 -50 0 Favours placebo
 
 
Analysis 3.5.   Comparison 3 Comfrey versus placebo, Outcome 5 WOMAC-VAS (Pain) change from baseline.
Study or subgroup Comfrey Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Grube 2007 110 12.1 (0) 110 2.7 (0) Not estimable
Favours comfrey 10050-100 -50 0 Favours placebo
 
 
Analysis 3.6.   Comparison 3 Comfrey versus placebo, Outcome 6 WOMAC-VAS (Sti>ness) change from baseline.
Study or subgroup Comfrey Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Grube 2007 110 4.8 (0) 110 1.2 (0) Not estimable
Favours comfrey 10050-100 -50 0 Favours placebo
 
 
Analysis 3.7.   Comparison 3 Comfrey versus placebo, Outcome 7 WOMAC-VAS (Function) change from baseline.
Study or subgroup Comfrey Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Grube 2007 110 43.4 (0) 110 10.7 (0) Not estimable
Favours comfrey 10050-100 -50 0 Favours placebo
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Analysis 3.8.   Comparison 3 Comfrey versus placebo, Outcome 8 WOMAC-VAS (Overall) change from baseline.
Study or subgroup Comfrey Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Grube 2007 110 60.4 (0) 110 14.7 (0) Not estimable
Favours comfrey 10050-100 -50 0 Favours placebo
 
 
Analysis 3.9.   Comparison 3 Comfrey versus placebo, Outcome
9 Change in SF-36 physical component summary score.
Study or subgroup Comfrey Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Grube 2007 110 11.9 (0) 110 1.3 (0) Not estimable
Favours placebo 105-10 -5 0 Favours comfrey
 
 
Analysis 3.10.   Comparison 3 Comfrey versus placebo, Outcome
10 Change in SF-36 mental component summary score.
Study or subgroup Comfrey Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Grube 2007 110 4.2 (0) 110 1.1 (0) Not estimable
Favours placebo 105-10 -5 0 Favours comfrey
 
 
Analysis 3.11.   Comparison 3 Comfrey versus placebo, Outcome 11 Participants (n) reported adverse events.
Study or subgroup Comfrey Placebo Risk Difference Risk Difference
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Grube 2007 7/110 15/110 -0.07[-0.15,0.01]
Favours comfrey 105-10 -5 0 Favours placebo
 
 
Comparison 4.   Marhame-Mafasel versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 WOMAC-VAS (Pain) change from
baseline
1 42 Mean Difference (IV, Fixed, 95% CI) -5.62 [-17.84, 6.60]
2 WOMAC-VAS (Stiffness) change
from baseline
1 42 Mean Difference (IV, Fixed, 95% CI) -14.3 [-28.22, -0.38]
3 WOMAC-VAS (Function) change
from baseline
1 42 Mean Difference (IV, Fixed, 95% CI) -1.09 [-9.40, 7.22]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4 WOMAC-VAS (Overall) change
from baseline
1 42 Mean Difference (IV, Fixed, 95% CI) -6.01 [-15.67, 3.65]
5 Participants (n) reporting ad-
verse events
1 42 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.25, 98.27]
 
 
Analysis 4.1.   Comparison 4 Marhame-Mafasel versus placebo, Outcome 1 WOMAC-VAS (Pain) change from baseline.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Soltanian 2010 21 -14 (18.4) 21 -8.4 (21.8) 100% -5.62[-17.84,6.6]
   
Total *** 21   21   100% -5.62[-17.84,6.6]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.9(P=0.37)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 4.2.   Comparison 4 Marhame-Mafasel versus placebo,
Outcome 2 WOMAC-VAS (Sti>ness) change from baseline.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Soltanian 2010 21 -21.1 (28.7) 21 -6.8 (15.3) 100% -14.3[-28.22,-0.38]
   
Total *** 21   21   100% -14.3[-28.22,-0.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.01(P=0.04)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 4.3.   Comparison 4 Marhame-Mafasel versus placebo,
Outcome 3 WOMAC-VAS (Function) change from baseline.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Soltanian 2010 21 -10.4 (13.3) 21 -9.3 (14.2) 100% -1.09[-9.4,7.22]
   
Total *** 21   21   100% -1.09[-9.4,7.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.26(P=0.8)  
Favours experimental 10050-100 -50 0 Favours control
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Analysis 4.4.   Comparison 4 Marhame-Mafasel versus placebo,
Outcome 4 WOMAC-VAS (Overall) change from baseline.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Soltanian 2010 21 -10.8 (16.6) 21 -4.8 (15.3) 100% -6.01[-15.67,3.65]
   
Total *** 21   21   100% -6.01[-15.67,3.65]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.22(P=0.22)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 4.5.   Comparison 4 Marhame-Mafasel versus placebo, Outcome 5 Participants (n) reporting adverse events.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Soltanian 2010 2/21 0/21 100% 5[0.25,98.27]
   
Total (95% CI) 21 21 100% 5[0.25,98.27]
Total events: 2 (Experimental), 0 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.06(P=0.29)  
Favours experimental 1000.01 100.1 1 Favours control
 
 
Comparison 5.   Stinging nettle versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 WOMAC 0-4 (Pain) at 1 week 1 42 Mean Difference (IV, Fixed, 95% CI) 2.0 [0.19, 3.81]
2 WOMAC 0-4 (Stiffness) at 4
weeks
1 39 Mean Difference (IV, Fixed, 95% CI) 0.90 [0.43, 1.37]
3 WOMAC 0-4 (Function) at 4
weeks
1 39 Mean Difference (IV, Fixed, 95% CI) 5.0 [0.90, 9.10]
4 Participants (n) reported ad-
verse events
1 42 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.20, 20.41]
 
 
Analysis 5.1.   Comparison 5 Stinging nettle versus placebo, Outcome 1 WOMAC 0-4 (Pain) at 1 week.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Randall 2008 21 8 (3) 21 6 (3) 100% 2[0.19,3.81]
   
Favours experimental 10050-100 -50 0 Favours control
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Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Total *** 21   21   100% 2[0.19,3.81]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.16(P=0.03)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 5.2.   Comparison 5 Stinging nettle versus placebo, Outcome 2 WOMAC 0-4 (Sti>ness) at 4 weeks.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Randall 2008 19 4.1 (0.8) 20 3.2 (0.6) 100% 0.9[0.43,1.37]
   
Total *** 19   20   100% 0.9[0.43,1.37]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.78(P=0)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 5.3.   Comparison 5 Stinging nettle versus placebo, Outcome 3 WOMAC 0-4 (Function) at 4 weeks.
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Randall 2008 19 33 (7) 20 28 (6) 100% 5[0.9,9.1]
   
Total *** 19   20   100% 5[0.9,9.1]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.39(P=0.02)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 5.4.   Comparison 5 Stinging nettle versus placebo, Outcome 4 Participants (n) reported adverse events.
Study or subgroup Experimental Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Randall 2008 2/21 1/21 100% 2[0.2,20.41]
   
Total (95% CI) 21 21 100% 2[0.2,20.41]
Total events: 2 (Experimental), 1 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.58(P=0.56)  
Favours experimental 1000.01 100.1 1 Favours control
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Comparison 6.   FNZG versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain on walking VAS 0-100 1 90 Mean Difference (IV, Fixed, 95%
CI)
-1.44 [-9.28, 6.40]
2 WOMAC 0-4 (Pain) 1 90 Mean Difference (IV, Fixed, 95%
CI)
-1.14 [-3.07, 0.79]
3 WOMAC 0-4 (Stiffness) 1 90 Mean Difference (IV, Fixed, 95%
CI)
-0.42 [-1.29, 0.45]
4 WOMAC 0-4 (Function) 1 90 Mean Difference (IV, Fixed, 95%
CI)
-2.61 [-9.50, 4.28]
5 WOMAC 0-4 (Overall) 1 90 Mean Difference (IV, Fixed, 95%
CI)
-4.22 [-13.70, 5.26]
6 Participants (n) reported adverse
events.
1 90 Odds Ratio (M-H, Fixed, 95% CI) 6.05 [0.32, 113.05]
 
 
Analysis 6.1.   Comparison 6 FNZG versus placebo, Outcome 1 Pain on walking VAS 0-100.
Study or subgroup FNZG patch Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 34.2 (17.9) 30 35.6 (17.9) 100% -1.44[-9.28,6.4]
   
Total *** 60   30   100% -1.44[-9.28,6.4]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
Favours FNZG 10050-100 -50 0 Favours placebo
 
 
Analysis 6.2.   Comparison 6 FNZG versus placebo, Outcome 2 WOMAC 0-4 (Pain).
Study or subgroup FNZG patch Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 7.5 (4.3) 30 8.6 (4.5) 100% -1.14[-3.07,0.79]
   
Total *** 60   30   100% -1.14[-3.07,0.79]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.15(P=0.25)  
Favours experimental 10050-100 -50 0 Favours control
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Analysis 6.3.   Comparison 6 FNZG versus placebo, Outcome 3 WOMAC 0-4 (Sti>ness).
Study or subgroup FNZG patch Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 2.6 (1.9) 30 3 (2) 100% -0.42[-1.29,0.45]
   
Total *** 60   30   100% -0.42[-1.29,0.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.95(P=0.34)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 6.4.   Comparison 6 FNZG versus placebo, Outcome 4 WOMAC 0-4 (Function).
Study or subgroup FNZG patch Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 19.8 (14.5) 30 22.4 (16.3) 100% -2.61[-9.5,4.28]
   
Total *** 60   30   100% -2.61[-9.5,4.28]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.74(P=0.46)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 6.5.   Comparison 6 FNZG versus placebo, Outcome 5 WOMAC 0-4 (Overall).
Study or subgroup FNZG patch Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 29.7 (20.1) 30 33.9 (22.4) 100% -4.22[-13.7,5.26]
   
Total *** 60   30   100% -4.22[-13.7,5.26]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.87(P=0.38)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 6.6.   Comparison 6 FNZG versus placebo, Outcome 6 Participants (n) reported adverse events..
Study or subgroup FNZG patch Placebo Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Wang 2012 5/60 0/30 100% 6.05[0.32,113.05]
   
Total (95% CI) 60 30 100% 6.05[0.32,113.05]
Total events: 5 (FNZG patch), 0 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.2(P=0.23)  
Favours experimental 1000.01 100.1 1 Favours control
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Comparison 7.   SJG versus placebo
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain on walking VAS 0-100 1 90 Mean Difference (IV, Fixed, 95%
CI)
1.08 [-6.24, 8.40]
2 WOMAC 0-4 (Pain) 1 90 Mean Difference (IV, Fixed, 95%
CI)
-1.80 [-3.62, 0.02]
3 WOMAC 0-4 (Stiffness) 1 90 Mean Difference (IV, Fixed, 95%
CI)
-0.37 [-1.19, 0.45]
4 WOMAC 0-4 (Function) 1 90 Mean Difference (IV, Fixed, 95%
CI)
-2.97 [-9.60, 3.66]
5 WOMAC 0-4 (Overall) 1 90 Mean Difference (IV, Fixed, 95%
CI)
-5.12 [-14.27, 4.03]
6 Participants (n) reported adverse
events
1 90 Odds Ratio (M-H, Fixed, 95% CI) 4.86 [0.25, 93.27]
 
 
Analysis 7.1.   Comparison 7 SJG versus placebo, Outcome 1 Pain on walking VAS 0-100.
Study or subgroup SJG Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 36.7 (14) 30 35.6 (17.9) 100% 1.08[-6.24,8.4]
   
Total *** 60   30   100% 1.08[-6.24,8.4]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.29(P=0.77)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 7.2.   Comparison 7 SJG versus placebo, Outcome 2 WOMAC 0-4 (Pain).
Study or subgroup SJG Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 6.8 (3.4) 30 8.6 (4.5) 100% -1.8[-3.62,0.02]
   
Total *** 60   30   100% -1.8[-3.62,0.02]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.94(P=0.05)  
Favours SJG 10050-100 -50 0 Favours placebo
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Analysis 7.3.   Comparison 7 SJG versus placebo, Outcome 3 WOMAC 0-4 (Sti>ness).
Study or subgroup SJG Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 2.6 (1.6) 30 3 (2) 100% -0.37[-1.19,0.45]
   
Total *** 60   30   100% -0.37[-1.19,0.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 7.4.   Comparison 7 SJG versus placebo, Outcome 4 WOMAC 0-4 (Function).
Study or subgroup SJG Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 19.4 (12.5) 30 22.4 (16.3) 100% -2.97[-9.6,3.66]
   
Total *** 60   30   100% -2.97[-9.6,3.66]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.88(P=0.38)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 7.5.   Comparison 7 SJG versus placebo, Outcome 5 WOMAC 0-4 (Overall).
Study or subgroup SJG Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 28.8 (17.5) 30 33.9 (22.4) 100% -5.12[-14.27,4.03]
   
Total *** 60   30   100% -5.12[-14.27,4.03]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.1(P=0.27)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 7.6.   Comparison 7 SJG versus placebo, Outcome 6 Participants (n) reported adverse events.
Study or subgroup SJG Placebo Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Wang 2012 4/60 0/30 100% 4.86[0.25,93.27]
   
Total (95% CI) 60 30 100% 4.86[0.25,93.27]
Total events: 4 (SJG), 0 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.29)  
Favours experimental 1000.01 100.1 1 Favours control
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Comparison 8.   FNZG versus SJG
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pain on walking VAS 0-100 1 120 Mean Difference (IV, Fixed, 95% CI) -2.52 [-8.24, 3.20]
2 WOMAC 0-4 (Pain) 1 120 Mean Difference (IV, Fixed, 95% CI) 0.66 [-0.73, 2.05]
3 WOMAC 0-4 (Stiffness) 1 120 Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.68, 0.58]
4 WOMAC 0-4 (Function) 1 120 Mean Difference (IV, Fixed, 95% CI) 0.36 [-4.49, 5.21]
5 WOMAC 0-4 (Overall) 1 120 Mean Difference (IV, Fixed, 95% CI) 0.89 [-5.74, 7.52]
6 Participants (n) reported adverse
events
1 120 Odds Ratio (M-H, Fixed, 95% CI) 1.27 [0.32, 4.99]
 
 
Analysis 8.1.   Comparison 8 FNZG versus SJG, Outcome 1 Pain on walking VAS 0-100.
Study or subgroup FNZG SJG Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 34.2 (17.9) 60 36.7 (13.9) 100% -2.52[-8.24,3.2]
   
Total *** 60   60   100% -2.52[-8.24,3.2]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.86(P=0.39)  
Favours FNZG 10050-100 -50 0 Favours SJG
 
 
Analysis 8.2.   Comparison 8 FNZG versus SJG, Outcome 2 WOMAC 0-4 (Pain).
Study or subgroup Experimental Control Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 7.5 (4.3) 60 6.8 (3.4) 100% 0.66[-0.73,2.05]
   
Total *** 60   60   100% 0.66[-0.73,2.05]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
Favours FNZG 10050-100 -50 0 Favours SJG
 
 
Analysis 8.3.   Comparison 8 FNZG versus SJG, Outcome 3 WOMAC 0-4 (Sti>ness).
Study or subgroup FNZG SJG Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 2.6 (1.9) 60 2.6 (1.6) 100% -0.05[-0.68,0.58]
   
Favours FNZG 10050-100 -50 0 Favours SJG
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Study or subgroup FNZG SJG Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Total *** 60   60   100% -0.05[-0.68,0.58]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.16(P=0.88)  
Favours FNZG 10050-100 -50 0 Favours SJG
 
 
Analysis 8.4.   Comparison 8 FNZG versus SJG, Outcome 4 WOMAC 0-4 (Function).
Study or subgroup FNZG SJG Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 19.8 (14.5) 60 19.4 (12.5) 100% 0.36[-4.49,5.21]
   
Total *** 60   60   100% 0.36[-4.49,5.21]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.15(P=0.88)  
Favours FNZG 10050-100 -50 0 Favours SJG
 
 
Analysis 8.5.   Comparison 8 FNZG versus SJG, Outcome 5 WOMAC 0-4 (Overall).
Study or subgroup FNZG SJG Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Wang 2012 60 29.7 (20.1) 60 28.8 (16.8) 100% 0.89[-5.74,7.52]
   
Total *** 60   60   100% 0.89[-5.74,7.52]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.26(P=0.79)  
Favours experimental 10050-100 -50 0 Favours control
 
 
Analysis 8.6.   Comparison 8 FNZG versus SJG, Outcome 6 Participants (n) reported adverse events.
Study or subgroup FNZG SJG Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Wang 2012 5/60 4/60 100% 1.27[0.32,4.99]
   
Total (95% CI) 60 60 100% 1.27[0.32,4.99]
Total events: 5 (FNZG), 4 (SJG)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.35(P=0.73)  
Favours experimental 1000.01 100.1 1 Favours control
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Species Plant part Preparations Dosage Treat-
ment du-
ration
Adverse
events
Arnica montana
Arnica chamis-
sonis
flower (fresh or
dried)
tincture
ointment
oil
3-10 times diluted
20-25% tincture or 15% oil
1:4 fatty oil
  skin reac-
tions
semi-liquid: 0.02-0.05% capsaicinoids 2 days
liquid: 0.005-0.01% capsaicinoids 14 days
Capsicum
species1
dried fruit extracts with
capsaicinoids
poultices: 10-40ug capsaicinoids/cm2 2-14 days
skin reac-
tions: local
hyperaemic
and nerve
damaging
Mentha arvensis fresh flowering
herb
essential oil2 several drops rubbed into the skin
5-20% oil or semisolid preparations
   
Mentha piperita fresh flowering
sprigs
essential oil3 several drops rubbed into the skin
dilutions in oil or semisolid preparations
  skin reac-
tions
Pica species4 tips of branches essential oil not stated   skin reac-
tions
Pinus species5 fresh boughs with
needles and tips
5-50% essen-
tial oil
several drops rubbed into the skin
dilutions in oil or semisolid preparations
  skin reac-
tions
herb and leaf 5-20% dried drug6Symphytum of-
ficinale
root
ointment
5-20% fresh or dried drug6
restrict-
ed to 4-6
weeks
None known
Urtica dioica
Urtica urens
herb and leaf
(fresh)
crude materi-
al
not stated    
Table 1.   Commision E approved monographs of medicinal plants for musculoskeletal complaints 
1. eg: C. fructescens.
2. 3-17% menthyl acetate, 42% menthol, 40% menthone.
3. 4.5-10% menthyl acetate, 44% menthol, 15-32% menthone.
4. P. arbies, P. excelsa, P. alba, P. sachalinensis, P. sibirica.
5.P. sylvestris, P. mugo, P. nigra.
6. with less that 100 µg pyrrolizidin alkaloids/day.
 
 
Species Starting material Preparations Dosage Treat-
ment du-
ration
Adverse
events
Arnica mon-
tana
flower with 4% helenalin
(sesquiterpene laactones)
tincture
ointment
cream
gel
dilutions from 5-25% tincture or fluid
extract: 1:3 to 1:10
  skin reac-
tions
Table 2.   ESCOP monographs for musculoskeletal complaints based on experimental and clinical studies 
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compress
liquid 0.025-0.075% capsaicinoidsCapsicum
species1
friut (dried) with not less
than 0.4% capsaicinoids
semiliquid poultice: 10-40ug capsaicinoids cm-2
3 weeks skin reac-
tions
local hyper-
aemic
Mentha
piperita
fresh flowering herb essential oil
1.25-16%2
several drops rubbed into the skin
dilutions in semi(liquid) preparations
  skin reac-
tions
Symphytum
officinale
root with up to 4.7% allan-
toin
ointment 35% root extract (DER 1:2, solvent
ethanol 60%) 3-4/day
restricted
in some
EU coun-
tries
None re-
ported
Urtica dioica
Urtica urens
fresh herb or leaf crude materi-
al
30 seconds / daily    
Table 2.   ESCOP monographs for musculoskeletal complaints based on experimental and clinical studies  (Continued)
1. eg: C. frutescens, C. annuum.
2. 30-55% menthol, 14-32% menthone, 2.8-10% menthyl acetate, 1-9% menthofuran, 3.5-14% cineol, etc.
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Botanical name Plant
part/s
Tradename Prepara-
tion
Drug/Ex-
tract
mg/day Constituent
marker
Quantity
of marker
Refer-
ences
Arnica montana (local) herb A. Vogel Ar-
nica Gel
tinc-
ture, 50%
ethanol1
20:1 3 x 4 cm not stated   Widrig
2007.
Capsicum species fruit Capsika gel extract,
ethanol
(concen-
tration not
stated)
0.0125% TID x 2
inches gel
capsaicin 0.365 Kosuwon
2010
Symphytum officinale (local) root Kytta Salbe f ethanolic
(60%) ex-
tract
2:1 6 (3 x 2mg) allantoin 0.2-0.5% Grube
2007.
Urtica dioica (local) leaf study med-
ication
crude leaf         Randall
2000, Ran-
dall 2008.
Arnebia euchroma +
Matricaria chamomilla + other medicinal plant parts
not stated Marhame-
Mafasel
not stated not stated 4500mg not stated   Soltanian
2010
rhizoma Arisaematis, radix Aconiti, flos Caryophylli,
cortex Cinnamomi, radix Angelicae dahuricae, herba
Asari, rhizoma Chuanxiong, radix Cynanchi panicuclati,
Olibanum, Myrrha, Camphora, Borneolum syntheticum.
see pre-
vious col-
umn
Fufang
Nanxing Zhi-
tong Gao
(FNZG)2
not stated not stated not stat-
ed (patch
10cm x
13cm)
hypa-
conitine
(C33H45NO10);
eugenol
(C10H12O2)
not stated Wang 2012
rhizoma Arisaematis, radix Aconiti, radix Angelicae
Dahuricae, cortex Cinnamomi, Camphora, Borneolum
Syntheticum, radix Angelicae Pubescentis, cortex
Acanthopanacis, rhizoma Curcuma Longae, flos
Carthami, folium Artemisiae
argyi, rhizoma Atractylodis, rhizoma Pinellia, semen Si-
napis, semen Vaccariae, radix Aconiti kusnezoffii, herba
Menthae.
see pre-
vious col-
umn
Shangshi Ji-
etong Gao
(SJG)2
not stated not stated not stat-
ed (patch
10cm x
13cm)
hypa-
conitine
(C33H45NO10);
eugenol
(C10H12O2)
not stated Wang 2012
Table 3.   Herbal medicinal products used for the treatment of osteoarthritis 
1. Information provided by manufacturer but not reported in paper.
2. Jiangsu Nanxing Pharmaceutical Company.
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FNZG patches for osteoarthritis of the knee
Patient or population: patients with osteoarthritis of the knee
Settings: Community, China
Intervention: FNZG patches
Illustrative comparative risks* (95% CI)
Assumed
risk
Corresponding risk
Outcomes
Control FNZG
Relative
effect
(95% CI)
No of Par-
ticipants
(studies)
Quality of
the evi-
dence
(GRADE)
Com-
ments
Pain
Pain on walking VAS 0-100
Follow-up: mean 7 days
  The mean pain in the inter-
vention groups was
1.44 lower
(9.28 lower to 6.4 higher)
  90
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Function
WOMAC 0-4 (Function)
Follow-up: mean 7 days
  The mean function in the in-
tervention groups was
2.61 lower
(9.5 lower to 4.28 higher)
  90
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Study populationAdverse events
Participants (n) reported ad-
verse events.
Follow-up: mean 7 days
0 per
1000
0 per 1000
(0 to 0)
OR 6.05 
(0.32 to
113.05)
90
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Adverse events
Participants (n) withdrew
due to adverse effects
Follow-up: mean 7 days
0/30 1/60 Not es-
timable
90
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Adverse events
Participants (n) reported seri-
ous adverse events
Follow-up: mean 7 days
    Not es-
timable
90
(1 study)
⊕⊕⊕⊝
moderate1,
2.
Reported
nil serious
adverse
events.
Quality of Life Not measured or reported.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Table 4.   Summary of findings: FNZG patches for osteoarthritis of the knee 
1 Single study.
2 Confirmatory design, statistical power 80%, alpha 0.05.
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SJG patches for osteoarthritis of the knee
Patient or population: patients with osteoarthritis of the knee
Settings: Community, China
Intervention: SJG
Illustrative comparative risks* (95% CI)
Assumed
risk
Corresponding risk
Outcomes
Control SJG
Relative
effect
(95% CI)
No of Par-
ticipants
(studies)
Quality of
the evi-
dence
(GRADE)
Com-
ments
Pain
Pain on walking VAS 0-100
Follow-up: mean 7 days
  The mean pain in the inter-
vention groups was
1.08 higher
(6.24 lower to 8.4 higher)
  90
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Function
WOMAC 0-4 (Function)
Follow-up: mean 7 days
  The mean function in the in-
tervention groups was
2.97 lower
(9.6 lower to 3.66 higher)
  90
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Study populationAdverse events
Participants (n) reported ad-
verse events
Follow-up: mean 7 days
0 per
1000
0 per 1000
(0 to 0)
OR 4.86 
(0.25 to
93.27)
90
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Adverse events
Participants (n) withdrew due
to adverse effects
Follow-up: mean 7 days
0/30 0/60 Not es-
timable
90
(1 study)
⊕⊕⊕⊝
moderate1,
2.
Reported
nil with-
drawals
due to
adverse
events.
Adverse events
Participants (n) reported seri-
ous adverse events
Follow-up: mean 7 days
0/30 0/60 Not es-
timable
90
(1 study)
⊕⊕⊕⊝
moderate1,
2.
Reported
nil serious
adverse
events.
Quality of Life Not measured or reported.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Table 5.   Summary of findings: SJG patches for osteoarthritis of the knee 
1 Single study.
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2 Confirmatory design, statistical power 80%, alpha 0.05.
 
 
FNZG patches versus SJG patches for osteoarthritis of the knee
Patient or population: patients with osteoarthritis of the knee
Settings:
Intervention: FNZG versus SJG
Illustrative comparative risks* (95% CI)
Assumed
risk
Corresponding risk
Outcomes
SJG FNZG
Relative
effect
(95% CI)
No of Par-
ticipants
(studies)
Quality of
the evi-
dence
(GRADE)
Com-
ments
Pain
Pain on walking VAS 0-100
Follow-up: mean 7 days
  The mean pain in the interven-
tion groups was
2.52 lower
(8.24 lower to 3.2 higher)
  120
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Function
WOMAC 0-4 (Function)
Follow-up: mean 7 days
  The mean function in the inter-
vention groups was
0.36 higher
(4.49 lower to 5.21 higher)
  120
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Study populationAdverse events
Participants (n) reported
adverse events
Follow-up: mean 7 days
67 per
1000
83 per 1000
(22 to 263)
OR 1.27 
(0.32 to
4.99)
120
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Study populationAdverse events
Participants (n) withdrew
due to adverse effects
Follow-up: mean 7 days
17 per
1000
0 per 1000
(0 to 0)
Not es-
timable
120
(1 study)
⊕⊕⊕⊝
moderate1,
2.
 
Adverse events
Participants (n) reported
serious adverse events
Follow-up: mean 7 days
0/60 0/60 Not es-
timable
120
(1 study)
⊕⊕⊕⊝
moderate1,
2.
Reported
nil serious
adverse
events.
Quality of Life Not measured or reported.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Table 6.   Summary of findings: FNZG patches versus SJG patches for osteoarthritis of the knee 
1 Single study.
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2 Confirmatory design, statistical power 80%, alpha 0.05.
 
 
Marhame-Mafasel for osteoarthritis of the knee
Patient or population: patients with osteoarthritis of the knee
Settings: Community, Iran
Intervention: Marhame-Mafasel
Illustrative comparative risks* (95% CI)
Assumed
risk
Corresponding risk
Outcomes
Control Marhame-Mafasel
Relative
effect
(95% CI)
No of Par-
ticipants
(studies)
Quality of
the evi-
dence
(GRADE)
Com-
ments
Pain due to OA:
change from baseline
WOMAC VAS (Pain;
higher means worse)
Follow-up: mean 3
weeks1
  The mean pain due to OA: change from
baseline in the intervention groups
was
5.62 lower
(17.84 lower to 6.6 higher)
  42
(1 study)
⊕⊕⊝⊝
low 2, 3
 
Function due to OA:
change from baseline
WOMAC VAS (Func-
tion; higher means
worse)
Follow-up: mean 3
weeks
  The mean function due to OA: change
from baseline in the intervention
groups was
1.09 lower
(9.4 lower to 7.22 higher)
  42
(1 study)
⊕⊕⊝⊝
low 2, 3
 
Study populationAdverse events
Participants (n) re-
ported adverse events
Follow-up: mean 3
weeks
0 per
1000
0 per 1000
(0 to 0)
RR 5.00
(0.25 to
98.27)
OR 5.51 
(0.25 to
122.08)
42
(1 study)
⊕⊕⊝⊝
low 2, 3
 
Adverse events
Participants (n) with-
drew due to adverse
effects
           
Adverse events
Participants (n) re-
ported serious ad-
verse events
           
Quality of Life Not measured or reported.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI: Confidence interval; OR: Odds ratio.
GRADE Working Group grades of evidence
Table 7.   Summary of findings: Marhame-Mafasel for osteoarthritis of the knee 
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High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Table 7.   Summary of findings: Marhame-Mafasel for osteoarthritis of the knee  (Continued)
1 Crossover trial: 3 week interventions arms, without washout period.
2 Single study.
3 Exploratory study design; power, eAect, and sample size not determined a priori.
 
 
Stinging nettle for osteoarthritis of the thumb
Patient or population: patients with osteoarthritis of the thumb1
Settings: Community, England
Intervention: Stinging nettle
Illustrative comparative
risks* (95% CI)
Assumed
risk
Correspond-
ing risk
Outcomes
Control Stinging net-
tle
Relative
effect
(95% CI)
No of Par-
ticipants
(studies)
Quality of
the evi-
dence
(GRADE)
Comments
Pain
VAS 0-100 (higher
means worse)
Follow-up: mean 1
weeks
The mean
pain in the
control
groups
was
37.04 mm
The mean
pain in the
intervention
groups was
13.37 lower
(0 to 0 higher)
  54
(1 study)
⊕⊝⊝⊝
very low1, 2,
3
 
Function Not measured or reported.
Adverse events
Participants (n) re-
ported adverse events
        ⊕⊝⊝⊝
very low1, 2,
3
Crossover trial: Participants
(n) with adverse events report-
ed for whole trial only (ie: both
arms of crossover combined).
Adverse events
Participants (n) with-
drew due to adverse
effects
Not measured or reported.
Adverse events
Participants (n) re-
ported serious ad-
verse events
        ⊕⊝⊝⊝
very low1, 2,
3
Reported nil serious adverse
events.
Quality of life         ⊕⊝⊝⊝
very low1, 2,
3
Crossover trial: HAQ reported
for whole trial only (ie: both
arms of crossover combined).
Table 8.   Summary of findings: stinging nettle for osteoarthritis of the thumb 
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Health Assessment
Questionnaire (HAQ)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI: Confidence interval.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Table 8.   Summary of findings: stinging nettle for osteoarthritis of the thumb  (Continued)
1 Single study.
2 Criteria for diagnosis of OA not specified at baseline. Other arthritides are possible confounders.
3 Most outcome data were reported as means only (not standard deviations) without confidence intervals. Data for first and second periods
were aggregated and are insuAicient for extraction from the first arm (up to crossover) only. We have presented aggregated data for pain
(VAS 0-100) aNer 1 week of intervention and re-calculated the mean diAerence between groups at this time point. We note that the mean
diAerence between groups is -13.37, not 15.08, which is the sum of the within-groups mean changes reported by the authors as mean
diAerence.
 
 
Stinging nettle for osteoarthritis of the knee
Patient or population: patients with osteoarthritis of the knee
Settings: Community, England
Intervention: Stinging nettle
Illustrative comparative risks* (95% CI)
Assumed
risk
Corresponding risk
Outcomes
Control Stinging nettle
Relative
effect
(95% CI)
No of Par-
ticipants
(studies)
Quality of
the evi-
dence
(GRADE)
Comments
Pain
WOMAC 0-4 (Pain; higher
means worse)
Follow-up: mean 1 weeks
  The mean pain due to OA in the
intervention groups was
2 higher
(0.19 to 3.81 higher)
  42
(1 study)
⊕⊝⊝⊝
very
low1,2,3,4
 
Function
WOMAC 0-4 (Function; high-
er means worse)
Follow-up: mean 4 weeks5
  The mean function due to OA in
the intervention groups was
5 higher
(0.9 to 9.1 higher)
  39
(1 study)
⊕⊝⊝⊝
very
low1,2,3,4
 
Study population
48 per
1000
95 per 1000
(9 to 557)
Adverse events
Participants (n) reported
adverse events
Follow-up: mean 1 weeks5
Moderate
RR 2.00
(0.20 to
20.41)
OR 2.11 
(0.18 to
25.17)
42
(1 study)
⊕⊕⊝⊝
low1,2,3,6
 
Table 9.   Summary of findings: stinging nettle for osteoarthritis of the knee 
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48 per
1000
96 per 1000
(9 to 559)
Adverse events
Participants (n) withdrew
due to adverse effects
          With-
drawals
due to
adverse
events not
measured
or report-
ed.
Adverse events
Participants (n) reported se-
rious adverse events
          Serious
adverse
events not
measured
or report-
ed.
Quality of life Not measured or reported.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention
(and its 95% CI).
CI: Confidence interval; OR: Odds ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
Table 9.   Summary of findings: stinging nettle for osteoarthritis of the knee  (Continued)
1 Diagnosis not consistent with ACR criteria. OA not distinguished from other causes of knee pain in older adults at baseline (presumptive
diagnosis). Although OA is the most likely cause of knee pain in older adults, other arthritides are possible confounders.
2 Exploratory study design; power, eAect, and sample size not determined a priori.
3 Placebo validity and blinding may be compromised by stinging eAect of active intervention.
4 Patients were follow up for pain and function measures at 4 and 16 weeks. In both intervention and control groups, further improvements
in these domains were identified at follow up time points. These long term improvements suggest that short term changes in pain and
function represent normal variation within individuals with OA, and are not of clinical importance.
5 1 week intervention, 15 weeks follow up.
6 Urtica dioica stimulates pain receptors in the skin, which is part of the eAect of this topical agent. "Stinging sensations" were not included
in reported adverse events, probably because participants understood that this eAect was likely with the the intervention. One participant
in the control group reported stiAness in the knee as an adversse event. StiAness is an expected outcome of untreated OA. These results
suggest that insuAicient blinding to the intervention may have confounded the reporting of adverse events.
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Appendix 1. Search Strategies
MEDLINE
1     exp osteoarthritis/
2     osteoarthr$.tw.
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3     (degenerative adj2 arthritis).tw.
4     arthrosis.tw.
5     or/1-4
6     exp Medicine, Herbal/
7     exp Plants, Medicinal/
8     exp Medicine, Traditional/
9     exp Drugs, Chinese Herbal/
10     herb$.tw.
11     (plant or plants).tw.
12     phytomedicine.tw.
13     botanical.tw.
14     weed$.tw.
15     algae.tw.
16     (fungi or fungus).tw.
17     ((traditional or chinese or herbal) adj medicine).tw.
18     ((oriental or chinese) adj tradition$).tw.
19     or/6-18
20     5 and 19
EMBASE
1     exp osteoarthritis/
2     osteoarthr$.tw.
3     (degenerative adj2 arthritis).tw.
4     arthrosis.tw.
5     or/1-4
6     exp Herbal Medicine/
7     exp Medicinal Plant/
8     exp Traditional Medicine/
9     exp Chinese Medicine/
10     herb$.tw.
11     (plant or plants).tw.
12     phytomedicine.tw.
13     botanical.tw.
14     weed$.tw.
15     algae.tw.
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16     (fungi or fungus).tw.
17     ((traditional or chinese or herbal) adj medicine).tw.
18     ((oriental or chinese) adj tradition$).tw.
19     or/6-18
20     5 and 19
CINAHL
1     exp OSTEOARTHRITIS/
2     osteoarthr$.tw.
3     (degenerative adj2 arthritis).tw.
4     arthrosis.tw.
5     or/1-4
6     exp Medicine, Herbal/
7     exp Plants, Medicinal/
8     Medicine, Traditional/
9     exp Plant Extracts/
10     herb$.tw.
11     (plant or plants).tw.
12     phytomedicine.tw.
13     botanical.tw.
14     weed$.tw.
15     algae.tw.
16     (fungi or fungus).tw.
17     ((traditional or chinese or herbal) adj medicine).tw.
18     ((oriental or chinese) adj tradition$).tw.
19     or/6-18
20     5 and 19
Revised Strategy (EBSCOhost)
S24 S5 and S22
S23 S5 and S22
S22 S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21
S21 ti chinese tradition* or ab chinese tradition*
S20 ti oriental tradition* or ab oriental tradition*
S19 ti herbal medicine or ab herbal medicine
S18 ti chinese medicine or ab chinese medicine
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S17 ti traditional medicine or ab traditional medicine
S16 ti fungi or ti fungus or ab fungi or ab fungus
S15 ti algae or ab algae
S14 ti weed* or ab weed*
S13 ti botanical or ab botanical
S12 ti phytomedicine or ab phytomedicine
S11 ti plant or ti plants or ab plant or ab plants
S10 ti herb* or ab herb*
S9 (MH "Plant Extracts+")
S8 (MH "Medicine, Traditional+")
S7 (MH "Plants, Medicinal+")
S6 (MH "Medicine, Herbal+")
S5 S1 or S2 or S3 or S4
S4 ti arthrosis or ab arthrosis
S3 ti degenerative N2 arthritis or ab degenerative N2 arthritis
S2 ti osteoarthr* or ab osteoarthr*
S1 (MH "Osteoarthritis+")
AMED
1     exp Osteoarthritis/
2     osteoarthr$.tw.
3     (degenerative adj2 arthritis).tw.
4     arthrosis.tw.
5     or/1-4
6     exp herbal drugs/
7     exp traditional medicine/
8     exp plant extracts/
9     exp plants medicinal/
10     herb$.tw.
11     (plant or plants).tw.
12     phytomedicine.tw.
13     botanical.tw.
14     weed$.tw.
15     algae.tw.
16     (fungi or fungus).tw.
17     ((traditional or chinese or herbal) adj medicine).tw.
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18     ((oriental or chinese) adj tradition$).tw.
19     or/6-18
20     5 and 19
The Cochrane Library 2008, Issue 4
#1           MeSH descriptor Osteoarthritis explode all trees
#2           osteoarthr*:ti,ab
#3           (degenerative near/2 arthritis):ti,ab
#4           arthrosis:ti,ab
#5           (#1 OR #2 OR #3 OR #4)
#6           MeSH descriptor Medicine, Herbal explode all trees
#7           MeSH descriptor Plants, Medicinal explode all trees
#8           MeSH descriptor Medicine, Traditional explode all trees
#9           MeSH descriptor Drugs, Chinese Herbal explode all trees
#10         herb*:ti,ab
#11         (plant or plants):ti,ab
#12         phytomedicine:ti,ab
#13         botanical:ti,ab
#14         weed*:ti,ab
#15         algae:ti,ab
#16         (fungi or fungus):ti,ab
#17         ((traditional or chinese or herbal) next medicine):ti,ab
#18         ((oriental or chinese) next tradition*):ti,ab
#19         (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18)
#20         (#5 AND #19)
ISI Web of Science
#7 #4 AND #1
Refined by: Publication Years=( 2009 OR 2007 OR 2004 OR 2001 OR 2010 OR 2005 OR 2003 OR 2000 OR 2008 OR 2006 OR 2002 ) AND Document
Type=( PROCEEDINGS PAPER OR MEETING ABSTRACT )
#6 #4 AND #1
Refined by: Publication Years=( 2009 OR 2007 OR 2004 OR 2001 OR 2010 OR 2005
#5 #4 AND #1
#4 #3 OR #2
#3 Topic=(((oriental or chinese or traditional) and (medicine or therap*)))
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#2 Topic=(herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus)
#1 Topic=(arthrit* or arthrosis or osteoarthrit* or osteoarthrosis)
Dissertation Abstracts
arthrit* or arthrosis or osteoarthrit* or osteoarthrosis AND
herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus or ((oriental or chinese or traditional) and
(medicin* or therap*))
World Health Organization International Clinical Trials Registry Platform
Osteoarthritis in Condition AND
herb* or plant or plants or phytomedicine or botanical or weed* or algae or fungi or fungus or oriental or chinese or traditional in
Intervention
W H A T ' S   N E W
 
Date Event Description
28 May 2013 Amended Minor changes to abstract
 
H I S T O R Y
Review first published: Issue 5, 2013
 
Date Event Description
12 March 2013 New citation required and conclusions
have changed
Substantive amendment; new authors.
27 February 2012 New search has been performed This updated review is divided into two parts: topical herbal
therapies and oral herbal therapies for treating osteoarthritis.
The original review included only 5 studies, one of which inves-
tigated extracted capsaicin, which is by the WHO definition not
herbal, so this study has been excluded (Deal 1991). This up-
dated review covers topical herbal therapies only. A total of 7
new studies were identified for inclusion in this updated review
(Grube 2007; Kosuwon 2010; Randall 2000; Randall 2008; Soltan-
ian 2010; Wang 2012; Widrig 2007). The main distinguishing fea-
tures of topical medicinal plant products are (a) the additional
skin irritant mechanism of action for some products, and (b) for
other products safety concerns when consumed orally.
The inclusion criteria have been expanded such that language of
publication is no longer a barrier to inclusion, studies using ac-
tive as well as placebo controls are included. Changes to meth-
ods of quality assessment (risk of bias), and presentation of re-
sults are consistent with updated Cochrane methods introduced
since the original review. The table of herbal interventions has
been extensively revised so that it offers detailed information
about the herbal medicines, including full botanical name, part
of the plant used, details of extraction methods, drug:extract ra-
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Date Event Description
tio, and content of marker substances of the active principle if
possible. This information is the minimum required to be able to
repeat the study.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
For this revew update, we expanded the inclusion criteria so studies that included an active control as well as placebo controls, and
unpublished reports of randomised controlled trials, were eligible for inclusion. Changes to the methods of quality assessment (replaced
by assessment of 'risk of bias') and analysis and presentation of results are consistent with updated Cochrane Collaboration and Cochrane
Musculoskeletal Group methods introduced since the original review. We restricted the included studies to those investigations of
interventions that strictly satisfy the WHO guidelines for herbal medicines. This updated review is limited to topical medicinal plant
products only.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Arnica;  Capsaicin  [therapeutic use];  Comfrey  [chemistry];  Drugs, Chinese Herbal  [administration & dosage];  Hand Joints; 
Osteoarthritis  [*drug therapy];  Osteoarthritis, Knee  [drug therapy];  Phytotherapy  [*methods];  Plant Extracts  [*administration &
dosage]
MeSH check words
Humans
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